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Abstract
COPPER SULFIDE MANGANESE NANOPARTICLES FOR
MULTIMODALITY IMAGING AND THERAPY
By Ali S. Gawi Ermi, MSc
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Chemical Biology at Virginia Commonwealth University.
Virginia Commonwealth University, 2021.
Major Director: Professor Jamal Zweit,
Departments of Radiology and Affiliate Professor, Department of Chemistry
Inorganic nanoparticles (NPs) are compatible with metal-based multi-modality molecular
imaging and targeted therapy. Copper sulfide nanoparticles (CuS NPs) are attractive photoacoustic
and photothermal agents and are amenable to incorporation of radionuclides and paramagnetic
elements to facilitate image-guided therapy. The aim of this work is to develop manganese (Mn)doped CuS NP, intrinsically radiolabeled with radionuclides such as (Zirconium-89 (89Zr), Copper64/67 (64/67Cu) and Manganese-52/55 (52/55Mn)). This novel approach combines Photoacoustic
(PA), Positron emission tomography (PET), Single-photon emission computed tomography
(SPECT) and magnetic resonance imaging (MRI) in one platform. Potentially, such a platform can
also accommodate therapeutic radionuclides and enable image-guided radionuclide therapy as well
as photothermal therapy (PTT). In this study, two radionuclides were intrinsically incorporated
into CuS-Mn NPs, 89Zr for PET imaging and 67Cu for SPECT imaging and potential radiotherapy.
Doping of Mn into CuS NPs (CuS-Mn NPs) provided an enhanced T1/T2 MRI contrast. The CuS
NP has a high absorption in the NIR region suitable for PA imaging and exhibits high photothermal conversion efficiency, adequate for PTT.
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A hydrothermal method was developed for the synthesis of 89Zr/67Cu labeled CuS-Mn NP,
by reacting Sodium Sulfide (Na2S) with Copper Chloride (CuCl2)/ Manganese Chloride (MnCl2)
in aqueous solution under existence of organic/polymeric ligand as a coating.

89

Zr or

67

Cu was

doped into NPs during the synthesis. Hydrodynamic (HD) size of the NPs was measured by
dynamic light scattering (DLS). Reaction yields were assessed by inductively coupled plasma
optical emission spectrometry (ICP-OES) and gamma counting. Multispectral Optoacoustic
Tomography (MSOT) signal was assessed as a function of NPs concentration. Animal PET
imaging and biodistribution were done at 30 min, 2 h, and 24 h post intravenous (i.v.) injection.
Stability of radiolabeled NPs in water, plasma and urine was evaluated by radio-high performance
liquid chromatograph (radio HPLC). Relaxivity characterization was done to study the
enhancement of MRI signal by CuS-Mn NP. Animal MRI was performed in mice before and 2 h
after injection of CuS-Mn NPs and T1 and T2 weighted MRI images were acquired.
The reaction yield of CuS-Mn NPs ranged from 80-90% as measured by ICP. The
radiolabeling yield of [89Zr]-CuS-Mn NP was > 63%. When labeling with the same chemical
element as the copper core, the radiolabeling yield of [67Cu]-CuS-Mn NP was almost quantitative.
Doping with Mn reduced HD size from 20 nm to ≈ 5 nm, as measured by size distribution DLS.
In a phantom study, the MR contrast signal was enhanced two-fold following injection of CuSMn NP compared to the bulk molecule MnCl2. The photoacoustic signal response was linear across
a NPs concentration ranging from 0.11 µg/ml to 10µg/ml of CuS-Mn NPs.
PET imaging of [89Zr]-CuS-Mn NP showed rapid renal clearance within less than 30 min
post injection. This rapid clearance has been facilitated by the ultra-small size (≈3-5nm) of the NP
being below the glomerular filtration rate. Enhancement of MRI images was demonstrated in liver
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and kidney at 2 hours post injection of the NP. CuS-Mn NP increased signal intensity and contrast
following i.v. injection into mice, with the signal intensity decreased over time.
Studies were also conducted with [67Cu]-CuS-Mn NPs, which have a larger size
distribution of 10-30 nm. Biodistribution of [67Cu]-CuS-Mn NPs showed rapid liver and spleen
uptake due to phagocytosis of larger particle size. Such accumulation resulted in increased
hepatobiliary clearance compared to the small NPs which are cleared more through the kidney.
The synthesis and intrinsic radiolabeling of CuS-Mn NPs, using either

89

Zr or

67

Cu has

been demonstrated. The feasibility of multi-modal capability with PET, MRI and PA imaging has
been demonstrated. This novel approach of intrinsically labelled radio-nanoparticles can be
expanded to incorporate a number of radionuclides and the platform can be modified to carry
targeting molecules, enabling the potential of target-specific imaging and therapy (Theranostics).
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Chapter 1: General Introduction
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1.1 Multimodality Copper Sulfide Manganese Nanoparticle
The merging of nanotechnology with targeted therapy and molecular imaging is gaining a
tremendous amount of interest within the biomedical research community. This is because the
potential for multi-targeting, controlled delivery and release can now be realized as a more rational
approach to the treatment of various diseases. This marriage is also leading to the development of
theranostic (“image as you treat”) approaches, which can contribute in precision and personalized
medicine1–4. The main motivation of this project is to exploit the combination of molecular
imaging and nanotechnology to develop a theranostic platform that could potentially be used in
combination therapy guided by molecular imaging. The nano-platform developed during the
course of this research has generated a novel multi-modal nanoparticle probe. It contains stable
and radioactive elements that can be detected by positron emission tomography (PET), singlephoton emission computerized tomography (SPECT), photoacoustic (PA) and magnetic resonance
(MR) imaging. This has been accomplished with a manganese doped copper sulfide nanoparticle
(CuS-Mn NP) that can intrinsically incorporate radionuclides for PET, Zirconiun-89 (89Zr), and
SPECT, copper-67 (67Cu) imaging. The MR and PA signals are provided by manganese (Mn), and
copper sulfide (CuS) respectively. The platform could also contain therapeutic radionuclides to
enable nano-radiopharmaceutical therapy guided by imaging (Theranostics).
1.2 Objectives
The overall objective of this project is to develop a novel multi-modal nanoparticle which
combines MR, PA, PET, SPECT signals in an “all in one” theranostic platform. The core/shell
CuS-Mn NP can be doped with PET radionuclides, such as 64Cu, 52Mn and 89Zr among others, to
afford PET imaging. It can also be doped with therapeutic radionuclides such as

67

Cu. CuS

provides efficient photo-absorption to enable both photoacoustic imaging and photothermal
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therapy, whilst doping with Mn allows MRI imaging. The novelty of this technology resides in the
fact that the MR, PET/SPECT and PA molecular imaging signals are all coming from the same
multi-elemental nanoparticle (Mn-MRI; CuS-PA; 67Cu-/64Cu-/89Zr-/52 Mn-SPECT/PET).
1.3 Hypothesis and Aims
We hypothesize that intrinsic labeling or doping of core/shell CuS NPs with radioisotopes
and contrast agents, would lead to the development of a multi-modality platform that merges
molecular imaging with nanotechnology. Furthermore, the use of therapeutic radionuclides, such
as 67Cu could also enable the combination of radiotherapy and photothermal therapy in the same
image-guided platform.
The following specific aims have been investigated to demonstrate the feasibility of the working
hypothesis:
1.1 Synthesis and physiochemical characterization of CuS NPs and CuS-Mn-doped NPs,
including size and charge analysis.
1.2 Optimization of intrinsic radiolabeling of CuS-Mn NPs with the radionuclides 89Zr and
67

Cu, as positron and single photon-emitting tracers respectively.

1.3 Evaluate the MR and MSOT imaging performance of Mn-doped CuS and determine
minimum amount of Mn needed for adequate MR signal.
1.4 Demonstrate imaging and radiotracer kinetics of radiolabeled CuS-Mn NPs in vivo and in
a live animal.
1.4 Research Strategy
Manganese-doped-CuS NPs (CuS-Mn) was synthesized with different coating materials
such as Poly (acrylic acid) (PAA), Alginic acid, Sodium Citrate, Polyethylene glycol (PEG), and
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intrinsically labeled with radionuclides such as

89

Zr,

67

Cu. Zirconium-89 (89Zr) is a positron-

emitting radionuclide with a half-life of 78.41 hours, which is used for PET imaging and ex vivo
biodistribution studies. Copper-67(67Cu) is a beta-emitting radioisotope which is attractive for
medical purposes due to its ability to carry sufficient radiation energy to cause cell death in targeted
cells while having a sufficiently short half-life of 62 hours, limiting radiation dose to patients.
67

Cu, incorporated in CuS-Mn NP was used as radiotracer tool to evaluate the chemical and

biological behavior of radiolabeled NP. CuS-Mn NP provided enhancement in both the PA and
MRI signals. To prepare a NP for future targeted imaging, preliminary experiments were
conducted to functionalize the CuS-Mn NP various coating, including polyethylene glycol (PEG),
or bovine serum albumin (BSA). To demonstrate peptide conjugation to the CuS-Mn NP, cyclo
(Arg-Gly-Asp) peptide (cRGD) peptide was used. This peptide has been previously used in our
laboratory, to target the alpha(V) beta (3) (αVβ3) integrins and imaged with PET and MRI.5
1.4.1 Extrinsically vs. Intrinsically Radio-labeled Nanoparticles
In order to radiolabel the nanoparticle with radionuclide, two main approaches have been
used (Figure 1). The first and most widely used radiolabeling strategy is extrinsically radio-labeled
nanoparticle, which involves the use of an exogenous linker that matches with certain isotopes to
form stable complex.6 Well known chelators, such as 1,4,7-triazacyclononane-1,4,7-triacetic acid
(NOTA),

1,4,7,10-

tetraazacyclododecane-1,4,7,10-tetraacetic

acid

(DOTA),

p-

isothiocyanatobenzyl- desferrioxamine (Df-Bz-NCS) and diethylene triamine pentaacetic acid
64

(DTPA), etc., have been used for radiolabeling of copper-64 ( Cu, t1/2 = 12.7 h), zirconium-89
89

111

( Zr, t1/2= 78.4 h) and indium-111 ( In, t1/2= 67 h) for imaging in preclinical studies.7,8 There
are many concerns of using traditional radiolabeling strategies include the possible changes of
chemical structure of the nanoparticle which lead to altering of in vivo pharmacokinetics of
4

carriers. In addition, the external label is on the surface of the nanostructure and is exposed to
chemical and enzymatic activity that may separate the radionuclide from the nanoparticle. This
could compromise the label’s usefulness for multi-modal imaging as the imaging systems such as
PET or SPECT detect signal from the radioisotope.9 Therefore, an alternative and successful
radiolabeling method is required to overcome with these limitations. The second strategy used in
this research intrinsically incorporates radionuclide into the core structure of the nanoparticle. The
focus here is on developing more reliable chelator-free radiolabeling technique, which could fully
take advantage of the unique physical and chemical properties of the nanoparticles for
radiolabeling, and more importantly, offer an easier, faster, and more specific radiolabeling
possibility. This will ensure effective shielding of the radionuclide within the nano-construct,
thereby providing a pharmacokinetic profile indicative of the overall nanoparticle. Additionally,
this will simplify the surface coating chemistry and offer a greater surface area for conjugation of
the targeting moiety. This intrinsic radiolabeling approach has been studied in Center of Molecular
Imaging (CMI) by using different radioisotopes with three types of NPs: cerium oxide NPs with
cerium-141, Indium-111, Zinc-65 and Zarconium-89, quantum dots with Indium-111, and
superparamagnetic iron oxide NPs with Iron-59 and Manganese-52.10–13

Figure 1: Extrinsically vs. Intrinsically Radio-labeled Nanoparticles. A) Externally labels
nanoparticle, by using linker (radioactive chelator). B) Internally incorporates the radioactivity
into the core of nanoparticle.
5

1.4.2 Intrinsically Radiolabeled Manganese-doped Copper Sulfide Nanoparticle
For intrinsic incorporation of radiolabeled CuS-Mn nanoparticles, 89Zr or 67Cu was used.
While the synthesis was optimized the 89Zr was used. The 89Zr isotope is a clinically relevant PET
imaging isotope and allows for both high activity PET imaging, and ex vivo biodistribution to more
precisely measure uptake in specific organs. 67Cu is a good candidate, chemically identical to the
CuS NP and does not affect chemical structure or physical properties of the nanoparticles. The
intrinsic radiolabeling strategy is more stable than using chelator to label the nanoparticle which
may cause change on the surface chemistry of the NP. This could increase the nanoparticle binding
with plasma proteins, increase the nanoparticle size, and change the pharmacokinetic profile.
1.5 Thesis Organization
This thesis contains eight chapters. The first chapter is a general introduction to the
research, including an overview of overall objective and strategy of the approach. Chapter two
provides an overview of cancer and nanotechnology and the impact of nanotechnology research
on cancer imaging, drug delivery and targeted therapy. Chapter three describes molecular imaging
techniques and their application in cancer imaging and therapy. Special emphasis is given to
techniques relevant to this project. Chapter four details the research approach and methods adopted
in this thesis. Chapter five describes the results of experiments, while chapter six focuses on
discussing the results of the research work and how it relates to the literature in the relevant
research area. Chapter seven outlines preliminary work on the synthesis of CuS-Mn NPs
conjugated with cRGD peptide for potential targeted imaging. Chapter eight provides an overall
summary and the way forward.
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Chapter 2: Cancer and Nanotechnology
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2.1 Cancer
Cancer is a group of diseases, which are characterized by uncontrolled and uncoordinated
cell division and growth. Cancer remains a major threat to human health and one of the most
leading causes of death. According to estimates from the International Agency for Research on
Cancer (IARC), in 2012 there were 14.1 million new cancer cases and 8.2 million cancer deaths
worldwide. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and
13 million cancer deaths14,15. In the last few decades, advances have been made in early diagnosis
and treatment of cancer. In the United States, this has resulted in improved survival rates for many
types of cancers16. Despite this, cancer is still a major killer, and there is still the need for more
advanced and effective diagnostic and therapeutic approaches to reduce the burden of the disease.
Cancer was and remains one of the challenges that face scientists. There are many theories studied
to answer and explain the behavior and nature of cancer cells, or at least to understand the
underlying mechanism of its occurrence and progression. One of the remarkable progress when
Hanahan and Weinberg published the hallmarks of cancer that allow normal cells to become
cancerous ones (Figure2). These characters which are shared in all types of cancer cells, sustaining
proliferative signaling, evading growth suppressors, avoiding immune destruction, enabling
replicative immortality, tumor-promoting inflammation, activating invasion and metastasis,
inducing angiogenesis, resisting cell death, deregulating cellular energetics, and genome instability
and mutation. By understanding and targeting these hallmarks of cancer which the main changes
occur in normal cell growth pathways, the treatment of cancer has been improved in most of
cancers17,18.
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Figure 2: Therapeutic Targeting of the Hallmarks of Cancer
2.2 Cancer treatments
Currently, cancer treatment involves surgery, chemotherapy, radiotherapy and biologically
targeted therapy19. Treatment options depend on a number of factors, including type and severity
of the disease, location of the disease and the overall health status of the patient concerned.
However, the problems of tumor recurrence, normal tissue damage and moderate to severe side
effects are still common among many cancer patients. In recent years, cancer immunotherapy has
emerged as a promising and effective approach for a number of cancers, especially melanoma and
lung cancer among others.20,21 Early cancer detection is still paramount, and all the evidence points
to the fact that early diagnosis, while the disease is still localized, can lead to better therapeutic
outcome. This is because controlling local disease, before tumor spread and metastasis, will always
be more effective than treating more advanced disease.22
Surgery: is usually the first treatment option. This can be done when the cancer is diagnosis in the
early stage and the cancer located only on one area and did not spread to other parts of the body.
However, not all surgeries result in complete removal of cancer cells and it is these residual cancer
cells that usually lead to recurrence. Some of these cell clusters are pre-cancerous stem cells which
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are never eradicated by surgery. Surgery also used for diagnosis of cancer where small piece of
the tissue called biopsy tested for the presence of cancer, type of cancer, and rate of growth.
Recent advances in targeting stem cell therapy are still at the experimental stage and the potential
of this approach could help eradicate the “roots” of cancer cells.23,24
Radiotherapy: is widely used in the treatment of cancer. The most commonly used approach is
external beam radiation therapy (EBR). The radiation used is called ionizing radiation because it
forms electrically charged particles to irradiate a field of view, previously planned by image
guidance using computed tomography (CT) or magnetic resonance imaging (MRI). This energy
can kill cancer cells or cause genetic changes (damages deoxyribonucleic acid, DNA) resulting in
cancer cell death. Advances in the physics of EBR has resulted in more beam focused therapy,
such is the case of confocal radiotherapy.25 In addition to CT and MRI, which provide excellent
morphological detail, high resolution positron-emission tomography (PET) has been applied to
determine functional volume of the tumor in order to guide a more effective EBR.26
Brachytherapy: is another type of radiation therapy and also known as internal radiation therapy
where the source of radioactive material is placed inside the patient body into or close to the tumor
to irradiate cancer cells. In this way the damage to normal cells can be reduced. Therefore,
brachytherapy delivers precise radiation doses to the tumor from the inside out. Brachytherapy can
be administered in different ways, including intracavitary, interstitially, intraluminal, and
intravascular.27 The duration of treatment is dependent on the half-life of the radio isotope placed
in the tumor area. Radioisotopes used in brachytherapy include, Iodine-125 (125I), Palladium-109
(109Pd), Iridium-192(192Ir), Cesium-131 (131Cs), and Gold-198 (198Au).28 The delivery of radiation
to the tumor site has been improved by incorporating of imaging modalities and delivery systems
such as nanoparticles.29,30
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Chemotherapy: is still a major treatment modality despite the failure of many therapeutic regimens
used. In general, chemotherapeutic drugs are usually, if not always associated with mild to severe
side effects. It is side effects is further exasperated by the fact that chemotherapy is cytotoxic and
does not discriminate normal from cancer cells. In advanced metastatic disease, it is given
systemically and hence all types of cells and tissue get exposed to the chemotherapy. Damage to
bone marrow, intestinal mucosa, and hair follicles is not uncommon. Damage to bone marrow cells
can cause anemia and affect immune system which lead to patient discomfort and more
importantly compromising the body defense mechanisms against for example “opportunistic”
infection.31 These side effects sometimes cause dose reduction and delay in treatment or
discontinuation of therapy. There are many types of chemotherapeutic agents which are classified
according to chemical nature and function, some of well know classes are listed in table 1. They
have been used in cancer treatment depending on the type of cancer and the mechanism of action
of the anticancer agents. The efficacy of chemotherapy agents depends on the drug concentration
against the specific site of the tumor. It is very important that chemotherapeutic agent be delivered
to the site of the cancer. This will minimize the exposure to surrounding normal and healthy
tissue.32 The use of drug delivery systems such as nanoparticles will help to deliver chemotherapy
agents to the tumor site and do not affect surrounding normal tissues. In clinical use there are
different types of the nanocarriers that used to deliver chemotherapies drugs and many others in
clinical trials. Examples of food and drug administration (FDA) approved nanomaterial
chemotherapy agents are liposomal doxorubicine (Doxil), liposomal irinotecan (onivyde), and
liposomal vincristine (Marqibo). Liposomes are the most widely used NP as a drug delivery
system33.
.
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Table 1: Classification of chemotherapeutic agents and mechanism of action (MOA) with the
examples.34
Type of the agent
Alkylating agents

MOA
Damage DNA
and prevent
mitosis.

Treatment of
leukemia,
lymphomas,
multiple
myeloma,
sarcoma and
lung, breast,
and ovarian
cancer

Examples
Nitrogen mustards such as
chlorambucil
Alkylsulfonates such as
busulfan
Nitrosoureas such as
streptozotocin
Triazines such as
dacarbazine
Ethylenimines such as
thiotepa and altretamine
Platinum drugs such as
cisplatin, carboplatin and
oxalaplatin

Antimetabolites

Interrupt the S
phase and
substitute normal
DNA and RNA
with other amino
acids.

Leukemia and
cancers of the
breast and
ovary

5-fluorouracil (5-FU), 6mercaptopurine (6-MP),
cytarabine, capecitabine,
fludarabine, gemcitabine,
methotrexate, pemetrexed,
pentostatin and
thioguanine.

Anti-tumor antibiotics or
Anthracyclines

Inhibit the
enzymes that
bring about DNA
replication

Lymphoma,
solid tumors,
bone and soft
tissue sarcomas

Doxorubicin,
daunorubicin, idarubicin
and epirubicin.

Topoisomerase inhibitors

Inhibit the
enzyme
topoisomerase

Leukemia and
lung, ovarian
and gut cancer

Topotecan, irinotecan,
etoposide and teniposide.

Plant alkaloids or Mitotic
inhibitors

Interrupt the M
phase of the cell
cycle and inhibit
mitosis

Breast and lung
cancers and
myeloma,
lymphoma, and
leukemia

Taxanes such as paclitaxel
and docetaxel, vinca
alkaloids such as
vinblastine, vincristine
and vinorelbine.
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Biological targeted therapy: as the name suggests, in this type of treatment a specific molecule is
targeted to the tumor site. Such molecules range from small to macro-molecules including
monoclonal antibodies and peptides. Targeting certain entities expressed on cancer cells may help
increase the specificity of these agents and reduce damage to healthy cells that do not express such
binding entities to the targeted agent. These molecules can stop the spread of cancer cells by
blocking specific molecules which involved in the growth of the cells and metastasis. For instance,
specific receptors which are only expressed on the surface of cancer cells can be identified and
targeted. Many molecules have been engineered to increase their selectivity and hence enhanced
binding to, for example receptors over-expressed by the cancer cells.35 Some targeting molecules
have been radiolabeled with therapeutic radioisotopes to produce targeted radio-pharmaceutical
therapy with beta- and alpha-emitting radioisotopes. 36,37. These molecular targeted therapies have
shown remarkable success in clinical use for treatment of breast, leukemia, colorectal, lung and
ovarian cancers. The main types of targeted cancer therapies are monoclonal antibodies, small
molecule inhibitors and immunotoxins.38,39
Radioimmunotherapy (RIT): In RIT uses specific monoclonal antibodies (MAbs) or antibody
fragments (peptides) against specific antigens on the surface of cancer cells, as targeting vehicles
of α- or β-emitting radionuclides. The MAbs or peptides linked to radioisotopes by using a chelator
to form radioimmunoconjugate (Figure 3). These radioimmunoconjugates are able to bind to
cancer cell surface and deliver the radiotherapy to the tumor and cause damage only to the targeted
cancer cells and not to the normal cells. The level of damage depends on the type of the
radionuclide and dose. For example, MAbs against prostate-specific membrane antigen (PSMA)
have been radiolabeled with Lutetium-177 (177Lu).40 PSMA is an antigen expressed on prostatic
cancer cells. 177Lu is a beta-emitting radioisotope with a half-life of (6.7 days) that is compatible
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with the in vivo kinetics of MAbs. Clinical experience with

177

Lu-PSMA in men with advanced

prostate cancer is encouraging.41 More recently, alpha-emitting radioisotopes have been used with
remarkable success in treating castrate- resistant metastatic prostate cancer. The use of the alphaemitter, Actinium-225 (225Ac) conjugated to anti-PSMA molecules has shown to be very promising
and effective against such metastatic disease.42 The combination of immunotherapy with
radiotherapy and chemotherapy has recently been proposed to enhance therapeutic effect in lung
cancer.43

Figure 3: The principles of radioimmunotherapy
Photothermal therapy (PTT): is a treatment modality in which tumors are ablated by heat following
absorption of light. Currently, several heating resources such as laser light, focused ultrasound and
microwaves have been employed in thermal cancer therapy. When heat is generated in the tumor
site, the ablation efficacy can be significantly enhanced. This can be achieved by targeting near
infrared (NIR) molecules. Compared with other therapeutic modalities, PTT shows high specificity
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and selectivity, with less damage to normal cells if the NIR molecule can be efficiently targeted
and retained at the tumor site.44 Photothermal agents can also be combined with chemotherapy or
radiotherapy to enhance efficacy of the treatment.45 The cancer cells become more sensitive to
radiotherapy or chemotherapy because of thermal stress, and this results in an improvement in
cancer survival rate. For example, photothermal with a combination of radiotherapy studies for
treatment of metastatic head and neck squamous cancers showed improvement results without
causing toxicity. Also, another enhancement was seen with phototherapy combined with
chemotherapy drugs for treatment of malignant melanoma.46 The massive invasion of heat could
cause damage for normal and healthy tissues. As a result, of whole-body hyperthermia
cardiovascular side effects and gastrointestinal symptoms can be seen. This makes conventional
PTT limited. Therefore, specific energy absorbing nanomaterials are needed, which can be in vivo
localized to target tumors to absorb energy and facilitate photothermal therapy.47,48
Recently, PTT has been used with the nanoparticles (NPs) to help with localized treatment
and minimize effect on normal tissues. Gold nanoparticles (Au NPs) have been developed as
effective PTT agents, and this is due to the fact that these NPs utilize the surface plasmon resonance
(SPR) which make them stronger absorption in visible and near infrared (NIR) regions.49 Copper
sulfide NPs (CuS NPs) have developed as a new class of PTT agents over the past few years. There
are three major advantages of CuS NPs in terms of their translational applications and compared
to Au-NP: i) consistent NIR absorption, ii) low cost, and iii) better degradability profile in vivo.
Instead of SPR effects, the NIR light absorption of CuS NPs derives from d-d energy band
transition of Cu2+ ions, and therefore the absorption wavelength of CuS NPs is not affected by the
size, particle shape, and surrounding environment. This feature can benefit the application of CuSNPs in different ways. First, in the CuS-NPs synthesis there is no need for control of morphology
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or shape to maintain SPR effects. Second, CuS-NPs can be made in smaller size (<10 nm), which
may lead to improve pharmacokinetic, biodistribution and fast renal clearance profile. This is
importance for toxicity concerns of NPs. Third, the stability and consistence of NIR absorption of
CuS-NPs in solutions, cancer cells, or in vivo environment, helps to better predict in vivo PT
properties of CuS-NPs based on in vivo experimental observations. Fourth, similar quantities of
CuS-NPs are about 200 times cheaper than that of Au-NPs, in term the cost of making.50,51 In
addition to the above consideration, the incorporation of imaging moieties into the NP platform is
essential because it provides for a direct means to examine not only the efficacy of the therapy,
but it also enables in vivo pharmacokinetics and underlying biology to be assessed non-invasively
in situ and within the intact in vivo environment.52 In this research, a promising multimodality
CuS-Mn NP will be studied which could be used for targeted localized PTT.
2.3 Emerging cancer therapies
Immunotherapy: in this type of cancer treatment the immune system for the patient is activated
to fight the tumor. These types of drugs are made by the body or in the laboratory to improve the
immune system by stopping the cancer from growing or spreading. There are several forms of
immunotherapy including cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated
T and natural killer cells, non-specific immunotherapies, and administration of antibodies or
recombinant proteins that either co-stimulate cells or block the so-called immune checkpoint
pathways.53,54 One of the most successful immunotherapeutic platforms is the use of monoclonal
antibody to block cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) which is a type of
immune checkpoint receptor or negative regulator of T-cell immune function. Another checkpoint
inhibitor antibody, nivolumab, a monoclonal antibody (mAb) which targets the programmed cell
death protein 1 (PD1) receptors on T-cells. Two of anti-PD-1 antibodies have been approved by
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the FDA for the treatment of metastatic melanoma and shows a higher survival rate. Many
immunotherapy treatments for preventing, managing, or treating different cancers can also be used
in combination with surgery, chemotherapy, radiation, or targeted therapies to improve their
effectiveness.55,56
2.4 Cancer nanotechnology
The study and application of materials in the nanoscale range (1-100’s of nanometer) is
known as nanotechnology. There are many applications of nanotechnology in cancer such as
prevention, diagnosis, therapy and combination of diagnosis and therapy (Theranostic).57 Recent
years have shown a tremendous expansion in the field of nanomedicine with the development of
various types of nanoparticles (NPs) geared towards both diagnosis and treatment of cancer.58
Compared to “bulk” molecules, NPs have unique physiochemical and biological properties given
their small size and large surface area-to-volume ratio.59 Such features allow them to bind, absorb,
and carry many types of chemicals, including proteins, small molecule drugs, DNA, ribonucleic
acid (RNA), and probes such as radioisotopes, and contrast agents. There are over 200
nanomaterials approved for clinical use and clinical trials.60 The first FDA approved nanomaterial
was Doxil, a nano formulation of liposome to deliver a chemotherapy drug (doxorubicin) to tumor
cells with less toxicity to normal cells61. A number of applications have been explored using NPs,
including drug delivery, targeted drug therapy, photo-thermal therapy as well as multi-modality
molecular imaging. Over the last decade, many types of organic and inorganic NPs have been
developed. These include metal- and polymer-based nanomaterials.62 The research described here
focuses on the development of the inorganic copper sulfide NP as a platform, which is amenable
to contain both therapeutic cargo and imaging moieties enabling image-guided studies.
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2.4.1 Nanoparticles
Nanoparticles (NPs) have unique physiochemical properties given their small size and
large surface area to volume ratio, which allows them to bind, absorb, and carry compounds such
as small molecule drugs, proteins, radioisotopes, and probes with high efficiency.63 Also, The NPs
have the ability to accumulate at the tumor by the enhanced permeability and retention (EPR)
effect, which means that they are better absorbed and dispersed within the tumor cells than normal
cells.64 Due to these unique properties, nanoparticle can combine cancer diagnosis and therapy in
one platform, a theranostic NPs.65 Theranostic nanoparticles (TNPs) are a multifunctional
nanomaterial which designed and characterized for disease management. They have ability to
combine diagnostic and therapeutic in one biocompatible and biodegradable nanoparticle.66 In the
last decades, there has been interest in the development of various types of theranostic
nanoparticles for cancer imaging and therapy. Effective targeting theranostic nanoparticles to
specific site (tumor) is crucial for both diagnosis and therapy. However, there are many
requirements for biocompatible TNPs with highly specific in vivo tumor-targeting capabilities,
which need to be realized. TNPs must accumulate rapidly and selectively at the target of interest,
report biochemical and morphological properties of the disease, site-specific drug delivery without
affecting healthy tissues. In addition, they must also have fast clearance from the body or to be
degraded to nontoxic byproducts. These NP features depend on a number of properties including
size and overall charge. Ultra-small NPs (HD size = 1-5 nm) are below the threshold of renal
clearance, while larger NP (e.g., >20 nm) are usually cleared through the hepatobiliary system 67,68.
Although, many types of TNPs have been developed over the last decades, few meet all the ideal
criteria. Nanoparticles have been made of different materials, organic nanomaterials or in organic
nanomaterials. For example, carbon nanotubes, quantum dots, liposome NPs, polymer NPs and
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metallic NPs (Figure 4). Among the metal-based NPs, gold NPs (AuNP) have been the most
developed and accelerated towards clinical trials. This is mainly due to their plasmonic effects and
high photothermal efficiency.69 NPs have also attracted attention in bioimaging and the most
studied in this regard include silica NPs gold NPs, cerium oxide NPs, magnetic NPs and polymer
NPs. Inorganic nanoparticles are compatible with incorporation of metals to facilitate multimodality molecular imaging and targeted therapy.70 They also offer the opportunity to incorporate
SPECT or PET imaging radionuclides to track and guide delivery of therapeutics.71

Figure 4: Different type of the NPs, organic nanoparticles and inorganic nanoparticles.72
2.4.2 Types of nanoparticles as a nanocarrier
There are many types of the nanoparticles which have been used as a drug delivery system,
liposomes and simple polymers were the first generation of the nanocarriers. Liposomes are
formed of phospholipids and they have a polar head and hydrophobic tail to form spheres. Their
size ranges are from ten nanometers to hundreds of nanometers. Liposomes have the ability to
deliver hydrophilic or hydrophobic drugs and their surface can be functionalized with polyethylene
glycol (PEG). This will help to increase their stability in vivo. The other first generation of the
nanocarriers is simple polymer which consists of natural polymers such as polysaccharides and
polypeptides that contain sugars and amino acids. For example, chitosan and albumin, in addition
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to polylactic acid and polyglycolic acid or a combination of both. This type of nanoparticles also
can be used as a drug delivery system for non-soluble treatment. The main advantage of liposomes
and polymers are biocompatible and biodegradable. Micelles are another type of complex polymer
which can be used as a drug nanocarrier. Micelles are made of self-assembling molecules that
contain hydrophobic and hydrophilic segments which are able to deliver hydrophilic and
hydrophobic drugs. A branched polymers nanoparticle also named dendrimers are a new
generation of the nanocarriers which are made of natural and non-natural components. The other
type of nanoparticles include metal or oxide-based nanocarriers (gold, copper, magnetic, quantum
dots, titanium dioxide, zinc oxide, and silica), carbon based nanocarriers (nanotubes and
fullerenes), and hybrids of materials such as lipid-coated or polymer-coated nanocarriers. 73,74
2.4.3 Copper sulfide nanoparticles CuS NPs
One of the metal-based NPs attracted in biomedical research is a CuS NP. It has a
multifunctional property and has been studied for different applications such as biosensing, DNA
detection, glucose detection, immunosensor, drug delivery, photoacoustic and photothermal
therapy. Also, they are merging and promising for combination diagnosis and therapy for cancer
(Theranostics).

75,76

They are attracted because of stability, easy synthesis, biocompatible, low

toxicity and low cost. 77,78 CuS NP has strong near-infrared (NIR) optical absorption (700-1100nm)
acquired from the d-d transition of Cu2+ ions and does not depend on morphology.77 However,
gold NP (AuNP) which is the most investigated metal-based NPs which is depends on surface
plasmon resonance (SPR).79 It is very important for the NPs to be cleared from the body to avoid
toxicity and accumulation. CuS NP showed fast and easy clearance and better biodegradable
compared to AuNP. This is due to non-metabolize nature of AuNP which related with their nonbiodegradable characteristics. On the other hand, CuS NP can be removed by hepatobiliary after
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metabolism of Cu by hepatocytes. 80,81 CuS NP has high photothermal conversion efficiency which
can be exploited for photothermal therapy. In addition,

64

Cu and

67

Cu radionuclides can be

integrated into CuS NP 82. These features make CuS NP an emerging as a multimodality platform
for imaging and therapy.
2.4.4 Nanotechnology for prevention and diagnosis of cancer
Nanoparticles can be used to prevent cancer disease by delivering tumor specific antigen
to the immune system to produce immune response against cancer. Also using the nanoparticle for
biosensing and diagnostic imaging will help with diagnosis of cancer. The example for biosensing
is by detecting specific cancer markers utilizing nanomaterials.83,84 The use of molecular imaging
improved detection and monitoring of the cancer treatment. Imaging systems utilizing various
types of nanoparticles because of their ability to generate imaging signals and their surface has the
ability to be functionalize with targeting molecules and some nanomaterials can produce more than
one signal, this makes them a multimodality that can be used for more than one imaging systems.
In addition, some nanomaterials have the ability to combine diagnostic and therapeutic agents.
Imaging systems that utilize iron oxide, gold nanoparticles, copper sulfide nanoparticles or carbon
nanotubes may have a theranostic value because these nanomaterials may be employed for therapy
in addition to imaging through their thermal ablation capabilities. New imaging modality such as
photoacoustic imaging are using nanoparticles as a contrast agent.85
2.4.5 Nanotechnology for cancer therapy
As mentioned in 2.1, the use of traditional therapeutic agents has been shown to have side
effects on the patients. The use of nanomaterials as nanocarriers for drug delivery may overcome
some of these problems. The advantages of using nanoparticles as a drug delivery system are: 1-
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To avoid drug degradation or solubility in vivo, the drug can be encapsulated within nanomaterials.
2-There surface can be functionalized with different molecules which are drugs, an imaging agent,
and a targeting moiety as a ligand or antibody. 3-The nanoparticles are able to accumulate at the
cancer site because of EPR effect properties. This is due to the fact that the gaps between
endothelial cells at the cancer site. This causes leakage of nanocarriers and gets retained there
because of defective lymphatic drainage, which results in passive targeting cancer tissue. 4-Active
targeting nanoparticles to target specific molecules expressed only on the surface of cancer cells.
For instance, folate receptor alpha (FRα) is a tumor marker expressed by certain epithelial cancers
while in normal tissue it is not accessible through the blood. In cancer, receptors on endothelial
cells have been targeted to remove cells from their blood supply. Examples for such receptors
include integrins α2bβ3, αvβ3, and α5β1. Actively targeting cancer cells or endothelial cells by
nanocarriers results in more effective therapy while avoiding nonspecific toxicity to normal cells.
5-Nanocarriers may overcome drug resistance by loading more than one drug onto
nanoparticles.86,87
The work described here is concerned with the development of doping manganese copper
sulfide nanoparticles (CuS-Mn NPs) for multimodality imaging and therapy. Such NP has inherent
near ideal properties including, stability, easy synthesis, high photothermal absorption,
biocompatibility, low toxicity and lower cost, compared to, for example gold NPs.82 Doping with
manganese enables MRI and the CuS core/shell can also accommodate radioisotopes of Cu, Mn
and other PET/SPECT/ radioisotopes. Copper and manganese are natural trace elements in the
body and are generally less toxic than heavier metals especially at low concentrations.88
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Chapter 3: Molecular Imaging
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3.1 Molecular imaging (MI)
Molecular imaging is a multidisciplinary field that combines chemistry, biology,
mathematics and medicine. It has the capability to visualize, characterize, and monitor biological
processes at the molecular and cellular levels and in real time in live subjects. The field has had a
huge impact, particularly in the last two decades, in the management of cancer patients. 89–91 The
use of [18F]-fluorodeoxyglucose (FDG)-PET for example, revolutionized cancer detection,
staging, and how best to monitor response to therapy. This is because, the technique can highlight
disease in any part of the body, thereby overcoming sampling limitations.92 The recent
development of total body PET/CT is a major advance in that it provides a snapshot of the whole
body faster and more quantitative than conventional PET.93 Clinically applicable molecular
imaging technologies include magnetic resonance imaging (MRI), positron emission tomography
(PET), and single photon emission computed tomography (SPECT). PET and SPECT are truly
molecular imaging modalities because they are based on specifically targeted radiotracers. MRI
and ultrasound (US) can obtain molecular and functional information when used with specifically
targeted contrast agents.94,95 Nowadays, PET and SPECT are combined with x-ray computed
tomography (CT) to provide functional information within a specific anatomical location. These
techniques use non-ionizing electromagnetic (MRI) and ionizing (CT, PET, SPECT) radiation with
infinite penetration and hence can detect deep seated legions. Fluorescence, bioluminescence,
photoacoustic and other optical-based techniques have wide applications in small animal imaging
and as of now they are not clinically viable due to limited penetration of light photons.96 Table 2
summarizes unique features of imaging technologies utilized in this project. Figure 5 shows the
spectrum of medical imaging which ranks the ability to image low concentrations (Sensitivity) of
specific molecules (Specificity).
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Figure 5: Schematic showing the spectrum of medical imaging which ranks the ability to image
low concentrations (Sensitivity) of specific molecules (Specificity).
Table 2: Characteristics of medical imaging modalities97
Imaging
Modality

Signal for
image
generation

Spatial
resolution

Temporal
resolution

Depth

Sensitivity

Type, Amount
of the probe

Magnetic
resonance
imaging (MRI)

Radiowaves

25–100 μm

minutes to hours

no limit

10−3–10−5
mole/L

activatable,
direct or indirect,
micrograms to
milligrams

Positron
emission
tomography
(PET)

High-energy γ
rays

1–2 mm

10 sec to minutes

no limit

10−11–10−12
mole/L

Radiolabeled,
direct or indirect,
nanograms

Single photon
emission
computed
tomography
(SPECT)

Low energy γ
rays

1–2 mm

minutes

no limit

10−10–10−11
mole/L

Radiolabeled,
direct or indirect,
nanograms

Photoacoustic
(PA)

Frequency sound
(laser excitation)

seconds to
minutes

mm to cm

seconds to
minutes

<1 cmh

not well
characterized,
likely 10−9–10−12
mole/L

50-500 μm

Optical
fluorescence
imaging

Visible light or
near-infrared

2–3 mmg
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not well
characterized,
likely 10−9–10−12
mole/L

limited
activatable,
direct,
micrograms to
milligrams

activatable,
direct or indirect,
micrograms to
milligrams

Table2: Continuous, Characteristics of medical imaging modalities
Imaging
Modality

Principal use

Advantages

Disadvantages

Clinical
Application

Quantitative
degree

Cost

Magnetic
resonance
imaging (MRI)

morphological
reporter/gene
expression,
receptor/ligand if
many receptors

highest spatial
resolution,
combines
morphological
and functional
imaging

relatively low
sensitivity, long
scan and
postprocessing
time, mass
quantity of probe
may be needed

Yes

++

$$$$

Positron
emission
tomography
(PET)

metabolic,
reporter/gene
expression,
receptor/ligand,
enzyme targeting

+++

$$$$

reporter/gene
expression,
receptor/ligand

PET cyclotron or
generator
needed,
relatively low
spatial
resolution,
radiation to
subject
relatively low
spatial resolution
because of
sensitivity,
collimation,
radiation

Yes

Single photon
emission
computed
tomography
(SPECT)

Yes

++

$$$

Photoacoustic
(PA)

melanoma and
lymph node
metastases

shielding by
strongly
absorbing
objects newer
technology with
few current
probes

Yes, but limited

++

$$-$$$

Optical
fluorescence
imaging

reporter/gene
expression, cell
trafficking

high sensitivity,
isotopes can
substitute
naturally
occurring atoms,
quantitative
translational
research
many molecular
probes available,
can image
multiple probes
simultaneously,
may be adapted
to clinical
imaging systems
spectral
information and
optical contrast
characteristics,
high resolution,
deeper into body
than
fluorescence
imaging
high sensitivity,
detects
fluorochrome in
live and dead
cells

relatively low
spatial
resolution,
surface-weighted

yes, but limited

+ to ++

$–$$

3.1.1 Magnetic resonance imaging (MRI)
The first clinical use of MRI was in 1980. Since then, MRI has become a widely use and
powerful tool to examine anatomical abnormalities caused by various diseases. MRI provides a
three-dimensional image with good soft tissue contrast and submillimeter spatial resolution that
can be used for diagnostic and therapeutic purposes. This is obtained by avoiding exposure to an
ionizing radiation. MR imaging applications include cardiac imaging, neuroimaging,
musculoskeletal imaging, to angiography.98–101
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The basic principle of MRI depends on the fact of that certain atomic nuclei, such as the
1

hydrogen nucleus ( H) which consists of proton and neutron with a net positive charge, and has a
property known as ‘‘spin’’. When the strong external magnetic field (B0), which usually ranges
from 0.2-7 Tesla (T), is applied to nucleus, their spin aligns in parallel or perpendicular to the
external field. A subject (tissue of the patient or animal) containing many nuclear spins, placed
within the B0 field, will have an extra spin in the same direction as B0. During their alignment, the
spins precession along this axis is under a specified frequency proportional to the magnetic field,
known as the Larmor frequency (ω0) which is calculated by equation (1).
[ω0= γ B0]

(1)
1

Where γ is the gyromagnetic ratio of the particles of interest ( H= 42.58 MHz/T) (Figure 6, A).
The image signal to noise ratio (SNR) depends on the strength of the fields (B0), where higher
strength fields result in higher image SNR which result in reduced radiofrequency field (RF)
homogeneity and increased specific absorption rate (SAR). Due to the introduction of RF to the
nuclei, the protons absorb energy and are excited to the transverse state (Figure 6, A). The excited
nuclei relaxed to their initial state, after the disappearance of the RF pulse. Two types of relaxation
pathways, longitudinal or T1 relaxation, including the decreased net magnetization in the zdirection recovering to the initial state (Figure 6, B). The transverse or T2 relaxation is the second
one, where the induced magnetization on the perpendicular plane (x y plane) decreases by the
dephasing of the spins (Figure 6, C). The two relaxation measurements are used to reconstruct
images where different tissues show different values for T1 and T2. T1 weighted images show better
differentiation for fatty tissues, while T2 weighted images are better for showing water
content.102,103
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Figure 6: A) Principle of MRI: spins align parallel or antiparallel to the magnetic field and precess
under the Larmor frequency; after introduction of the RF pulse the magnetization of the spin
changes; excited spins undergo both T1 and T2 relaxation processes. B) T1 relaxation of protons
which is shortened under the presence of T1contrast agents (e.g., Gd), which will generate a
brighter image. C)T2 relaxation of protons is shortened under the presence of T2 contrast agents
(e.g., Fe3O4 NPs), which will generate a darker image.104
3.1.2 Contrast agents for MRI
The endogenous MR contrast of different tissues has been shown more flexibility than in
other clinical imaging systems; nevertheless, to detect pathologies the utilization of exogenous
contrast metals which are able to differentiate the normal and diseased tissues by modifying their
intrinsic parameters are required. The metal contrast agent efficiency depends on their longitudinal
(r1) and transverse (r2) relaxivity, which are defined as the increase of the nuclear relaxation rate
(the reciprocal of the relaxation time) of water protons produced by one mmol/l of contrast agent.
The contrast agents are classified as T1 or T2 based on their relaxation processes.105
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Contrast-enhanced MRI is widely used to diagnose soft tissue and vascular
abnormalities.106 To enhance the contrast in MRI images, paramagnetic compounds, with a large
number of unpaired electrons, such as gadolinium (Gd)-based compounds, are desirable as contrast
agents because they can shorten the longitudinal relaxation time (T1) and the transverse relaxation
time (T2), and increase tissue signal intensity on T1 weighted images. However, safety concerns
limit the use of Gd-based and iodinated (I) MRI contrast media in renal compromised patients.
More recently, a number of reports have identified dose dependent Gd accumulation in the brains
of patients with normal renal function that have received contrast-enhanced MRI, raising further
concerns by the FDA regarding this class of compounds. Gd retention in a subset of patients further
underscores the need for a Gd-free alternative to enhance MR contrast.107,108 Therefore, a new
enhanced and safe contrast agent, compatible with renal impairment is sorely needed.
The transition metal ion manganese (Mn2+), with five unpaired electrons, can produce a
very efficient positive contrast enhancement and offers an attractive alternative to Gd-based MRI
contrast agents. Manganese is a trace micronutrient in the human body that, along with other
transition metals (Fe, Cu, and Zn), play essential roles in health and disease. In this sense, Mn is
a biologically relevant micronutrient metal ion and therefore has a much lower toxicity than
lanthanides or other heavy metals. In fact, Manganese chloride (MnCl2) has been approved by the
FDA as a T1 contrast agent. In addition to MnCl2, most other Mn-based MRI contrast agents have
predominately been developed as coordination complexes with acyclic or macrocyclic ligands.
Some recent developments have been based on different forms of Mn-based nanoparticles, such
as manganese oxide (MnO), manganese trioxide (Mn2O3) and manganese sulfide (MnS).109,110
Despite this, Mn-based agents developed so far, did not translate into clinical use because of
modest contrast enhancement at low safe doses, and if used at higher concentrations, they tend to
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induce toxicity particularly in the brain, a condition called (Manganism). Therefore, the hypothesis
here is that a trace Mn content within a safe and biologically compatible metal platform, could
provide high contrast at low doses. Accordingly, previously developed intrinsic nanoparticle (NP)
labeling technology will be exploited to develop a new CuS nanoparticle doped with trace amount
of Mn (CuS-Mn NP), as a novel platform with 1.5-2-fold higher contrast enhancement than the
commercially available Gd-based MRI contrast agents. In this project, we present the development
of a new copper sulfide-doped manganese (CuS-Mn) nanoparticle with ultra-small size and
biocompatible coating that facilitates rapid renal clearance. The product is a novel and safe MRI
contrast agent with a dual photoacoustic imaging (PAI) capability.
3.2 Positron emission tomography (PET) and Single Photon Emission Tomography
(SPECT)
These molecular imaging modalities have been used to study and understand biological
function and disorders of living tissue in health and disease. PET and SPECT are widely used for
the diagnosis of various diseases, including neurogenerative disorders, cardiovascular diseases and
cancer among others. A key component of PET or SPECT is the radiotracer which consists of the
biochemical compound of interest labeled with a PET or SPECT radionuclide respectively. PET
and SPECT will be disused in details in the following sections.
3.2.1 Positron emission tomography (PET)
The principle of PET imaging is based on the use of radionuclides coupled to chemical
compounds to produce radiotracers that decay by positron emission (Table 3). When a radiotracer
labeled with a radionuclide, such as Fluorine-18 (18F), or Zirconium-89 (89Zr), is injected into a
patient, a PET scanner can detect and track the signal from such radiotracer in different organs and
tissues. As an example, the decay schemes of

18
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F and

89

Zr are shown in figure 7, A and B.

Following positron decay, the positron travels a certain distance (determined by their kinetic
energy) and collides with a negative electron in tissue. The result of this is the annihilation of both
particles and the production of annihilation radiation in the form of two gamma rays with an energy
of 511 keV emitted at opposite directions. These photons are detected in coincidence by a PET
scanner using opposing pairs of detectors in a ring system. The principle of PET coincidence
detection and imaging is illustrated in (Figure 7, C). 111,112
The

activity

distribution

of

the

radionuclide

represents

an

image

of

the

tracer

distribution/concentration that provides an insight into the physiology and/or pathology in the
patient.
Table 3: The characteristics of commonly used PET radionuclides.
Nuclide Half-life
C
13
N
15
O

20.3 min
10 min
2 min

Decay
Modes
β+
β+
β+

18

F

109.8 min

EC, β+

0.634 (96.7%)

Mn
89
Zr

5.6 days
3.27 days

EC, β+
EC, β+

0.575 (29.6%)
0.90 (22%)

11

52

Maximum positron
(MeV) and yield (%)
0.961 (99.8%)
1.20 (99.8%)
1.74(99.9%)

64

12.7 hrs
EC, β+, β0.653 (17.4%)
+
4.2 days
EC, β
2.14 (23.0%)
+
β : beta-plus; β : beta-minus; EC: Electron Conversion
Cu
124
I

A

B
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energy Production
14

N(p,α)11C
16
O(p, α)13N
15
N(p,n)15O
14
N(d,n)15O
18
O(p,n)18F
20
Ne(d, α)18F
52
Cr(p,n) 52Mn
89
Y(p,n)89Zr
89
Y(d,2n)89Zr
64
Ni(p,n)64Cu
124
Te(p,n)124I

C
Figure 7: A) Decay scheme of Fluorine-18. B) Decay schemes of Zerconium-89. C) Principle of
PET imaging: positron emitting radionuclide yields a positron that travels a short distance, before
colliding with an electron which results in the annihilation of both particles and the production of
two collinear 511 keV photons. These photons exit the body and are detected by an array of
scintillation crystals.
3.2.2 Single Photon Emission Tomography (SPECT)
The fundamental basis for SPECT imaging is the detection of mono-energetically emitted
γ-rays from intravenously injected exogenous radionuclides (Table 4), ex. Iodine-123 (

123

I)

(Figure8, A) or Technetium-99m (99mTc) (Figure8, B). Gamma-ray photons emitted from the
internal distributed radiopharmaceutical penetrate through the animal’s or patient’s body are
detected by a single or a set of collimated radiation detectors. The collimator defines the angle of
incidence of the γ-rays emitted. Most of the detectors used in current SPECT systems are based on
multiple sodium iodide (NaI) (TI) scintillation crystal detectors. Upon interaction with the γ-rays,
these crystals emit light which is amplified by photomultiplier tubes and converted to electronic
signals. 2D images are acquired by rotating the gamma camera at different angles. These are then
converted to 3D image data set using tomographic reconstruction algorithms (Figure 8, C). 113
In SPECT, data are acquired from different views around the animal/patient and physical
collimation is used to project the signal emanating from specific field of view. Some of the emitted
γ-rays will be absorbed by the lead collimation, and it is because of this, SPECT imaging has a
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lower detection efficiency than PET, where electronic collimation is used to detect two coincident
γ-rays. Therefore, PET systems have higher sensitivity and higher resolution than SPECT cameras.
However, the use of radionuclide generators and medium half-life radionuclides, combined with
lower cost of gamma cameras, make SPECT imaging much more widely available for clinical use
than PET scanners. 114
Table 4: The characteristics of SPET radionuclides
Nuclide Half-life

Decay
Modes

Maximum energy (MeV)

Production reaction

67

61.83 hrs
6 hrs

β-, γ
g

0.5617
0.1405

68

Cu
Tc

99m

99

Zn (γ, p)
Mo/99mTc

123

I

13.3 hrs

EC, γ

0.16

127

198

Au

2.7 days

β-, γ

0.960

197

111

In

67.9 hrs

EC, γ

0.17/.0.25

111

153

Gd

240.4 days

EC, γ

0.10

152

78.3 hrs

EC, γ

0.09/0.19/0.30

68

67

+

Ga

-

β : beta-plus, β : beta-minus, EC: Electron Conversion, γ: gamma rays
A

B
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I(p,5n)
Au (n, γ)
Cd (p,n)
Gd (n, γ)

Zn(p,2n)

C

Figure 8: A) Decay scheme for single photon emitting radionuclides Indium-123 (A), and
Technetium-99m (B). C) Principle of SPECT imaging.
3.2.3 Radiotracers
Radiotracers are chemical compounds labeled with radionuclides which enable PET and
SPECT imaging techniques to be used, non-invasively, to visualize, study and diagnose various
disease conditions. Table 5 lists a number of commonly used radiotracers for PET and SPECT.
These range from simple thyroid imaging using a

99m

Tc-pertechnetate or iodide ion to more

complex metabolic and receptor-based radiotracers. For instance, fluorine-18-fluorodeoxyglucose
([18F]-FDG) is used for PET imaging of various cancers because the radiotracer is preferentially
taken up by cancer cells due to their greater metabolic activity compared to normal cells.115,116
Among the recently developed molecularly targeted radiotracers, gallium-68-prostate specific
68

membrane antigen ( Ga-PSMA) has shown high sensitivity and specificity for prostate cancer
detection and for monitoring response to therapy because it is taken up by specific membrane
antigen over-expressed on the prostate cancer cells.117,118
There is a continuous development of radiotracers for molecular imaging, including the
exciting combination of radiolabeled nanoparticles with drug nano-delivery systems for multimodality image-guidance of multiple therapeutics and drug “cocktails”. The introduction of
nanotechnology into radiotracer research has opened new possibilities of solid phase chemistry,
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microreactors and flow chemistry techniques to synthesis radiotracers.119 The incorporation of
radionuclides, contrast agents and therapeutic drugs has opened up the potential of multi-functional
nano-based agents including radiopharmaceuticals for imaging and therapy (theranostics). This
thesis is contributing to this effort by the development of a novel multi-modality intrinsically
labeled nanoparticle which encompasses an ‘’all in one” platform for multi-modal imaging by
PET, SPECT, MRI and photoacoustic imaging.
Table 5: Common radiotracers used in medical imaging
Radiopharmaceutical

Common clinical use

Mechanism of uptake

Tc-99m pertechnetate or
Sodium iodide-123/131
pertechnetate

Thyroid gland imaging

Trapping by Active transport

Tc-99m methylene
99m
diphosphonate ( Tc-MDP)

Bone imaging

Adsorption by hydroxyapatite
crystals

Tc-99m macroaggregated
99m
albumin particles ( Tc-MAA)

Lung perfusion imaging

Blockage of capillaries and
precapillary arterioles

Tc-99m(mercaptoacetyltriglycine)
99
mTc-MAG-3

Renal dynamic imaging

Tubular excretion

Tc-99m or In-111 labeled white
blood cells and monoclonal
antibody
Fluorine-18 fluorodeoxyglucose
18
([ F] FDG)

Infection imaging

Cell migration

Tumor imaging

Active transport to cells
(glucose analog)

Fluorine-18 sodium fluoride
18
([ F] NaF)

Bone imaging

Ion exchange

Gallium-68-PSMA( GaPSMA)

Prostate cancer imaging

Receptor binding

Gallium-68- octreotide/
edotreotide (68Ga-NOC/TOC)

Neuroendocrine tumor imaging

Receptor binding

Zr-89-labeled monoclonal
antibody

Immune PET imaging

Receptor binding

68
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3.3 Optical imaging
Optical imaging is another type of molecular imaging using optical technology noninvasively to visualize and characterize biological processes at the cellular and molecular level.
Using non-invasive and non-toxic imaging methods allows researchers and clinicians to study and
examine inside the system over the time without any modification or interactions in the tissues or
their microenvironments. This real time imaging is important especially for the examination of
diseases such as cancer. Deferent types of optical imaging such as florescence imaging,
bioluminescence imaging and optoacoustic imaging, use various techniques which depend on
illumination light in the ultraviolet, visible and infrared regions of the electromagnetic spectrum.
In the florescence imaging, the light illuminates on the subject or tissue within the range of the
wavelength between 395-600 nm and the emitted light with wavelength higher than excited
wavelength will be detected by charged coupled device (CCD) detectors. Near infrared probes can
be used to maximize tissue penetration. In bioluminescence imaging, the emission light only
detected by CCD because bioluminescence is a light producing phenomenon which occurs
naturally in many species whereas the oxidation of substrate (luciferin) by enzyme (luciferase),
photons are released as the substrate returns to its ground state from its excited state. Commonly
used probes for bioluminescence are reporter genes such as firefly or renilla luciferase (Fluc or
Rluc). Optoacoustic technology principle based on using pulsed laser to excite light on the subject
and as a result an ultrasound emitted and detected.91,120 In this work, MSOT was used for
photoacoustic imaging, and will be discussed in detail in the following section.
3.3.1 Multi-spectral optoacoustic tomography (MSOT)
Over the last decade, MSOT has been developed by combining high sensitivity optical
detection with high resolution ultrasound imaging.121 This technology works by using a pulsed
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laser light (1-100 nanoseconds) to illuminate tissue or an entity within. The technology can utilize
either endogenous compounds such as oxygenated & deoxygenated hemoglobin, and melanin, or
use exogenous agents with photoacoustic properties such as imaging probes and nanoparticles.
The principle of MSOT imaging is outlined in figure 9. First, the electromagnetic energy
from the laser light is absorbed by a photo-absorber in tissue, and part of this energy is converted
to heat. This causes thermo-elastic expansion, a phenomenon known as the optoacoustic or
photoacoustic effect, creating a pressure wave that is detected by ultrasound sensors. The detected
wave is converted into an image of the initial pressure distribution in the tissue using tomographic
inversion methods.122,123 Image formation can be done by means of hardware (e.g., acoustic
focusing or optical focusing) or computed tomography (mathematical image formation). MSOT
has the ability to illuminate tissues with various wavelengths, which allows the detection of
ultrasound waves emitted by different photo-absorbing molecules. Optoacoustic imaging based on
collecting ultrasound waves in the 0.1–10 MHz range achieves a resolution of about 300 microns
through 1-3 cm of tissue in the near-infrared (NIR) region, since sound scattering in tissue is orders
of magnitude lower than photon scattering. Compared with other conventional optical imaging
techniques, MSOT is not affected by photon scattering and as a result of this, high-resolution
optical images in reasonably deep biological tissues will be obtained.122 MSOT biological
applications include studies in cardiovascular disease research, neuroimaging, and cancer research,
among others.124–127 In addition, prototype clinical use of MSOT for imaging the breast,
vasculature, lymph nodes and skin, by real-time handheld imaging systems, has been recently
demonstrated.128,129
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B

A

Figure 9: A) Principle of MSOT operation. Illuminating the tissue at multiple wavelengths can
stimulate ultrasound wave emission by several photo-absorbers, leading to more informative
imaging than single-wavelength illumination. B) A number of endogenous compounds has
different absorption coefficient that compatible with MSOT.

3.3.2 MSOT contrast agents
Light absorbing molecules capable of converting light to a pressure wave have the potential
to be detected leading to the formation of an optoacoustic signal. Contrast agents absorbing light
in the NIR are particularly attractive, because the high wavelength in the NIR region enables
imaging at greater depth. Contrast agents with this feature help to expand the range of MSOT
imaging applications. Contrast agents can either be endogenous, that is light absorbing molecules,
which are naturally present in animal or humans, or they can be exogenous compounds
administered to the subject.

3.3.2.1 Endogenous contrast agents
A number of endogenous compounds have different absorption coefficients that are
compatible with MSOT shown in figure 9, B. One of the most commonly used endogenous contrast
agents for optoacoustic imaging is hemoglobin which is a dominate absorber of light in the visible
and NIR of the optical spectra. Hemoglobin, as a contrast agent allows sensitive imaging of
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vascular anatomy at various levels. Furthermore, MSOT has multispectral capability that allows
differentiation between oxygenated versus de-oxygenated hemoglobin. This is a unique tool which
can assess tissue oxygenation level and hypoxia (reduced oxygen), hence providing a functional
measure of oxygen status in normal and pathological physiology. Many useful applications for
using hemoglobin-based imaging, such as resolve vascular abnormalities and oxygenation status,
as

well

as

perfusion

imaging,

inflammation

imaging,

and

tumor

detection

and

characterization.123,130 Another endogenous contrast agent is melanin, which has the ability to
absorb over abroad range of the wavelength in the visible and NIR and the absorption decreases
with higher wavelength. There are different uses of melanin based optoacoustic imaging such as
to assess the depth of melanoma ingrowth inside epithelial tissue, and to assess the metastatic status
of sentinel lymph nodes in melanoma patients, also to detect circulating melanoma cells.131 More
endogenous absorbers can be detected by MSOT. For example, lipids which can be imaged at NIR
wavelengths with absorption peak of 930 nm, and water which has strong absorption at NIR
wavelengths and higher peak at 980 nm. Bilirubin and cytochromes can be imaged at blue
wavelengths. DNA absorbs UV which is exploited to image cell nuclei.132,133
3.3.2.2 Exogenous contrast agents
A large numbers of exogenous contrast agents have been developed and are under
development for optoacoustic imaging, examples of imaging probes have been reported in table 6.
The absorption spectrum for these contrast agents is different from that of endogenous ones and
this makes them easily separated from other background absorbers using spectral unmixing.
Organic dyes, such as the fluorochromes indocyanine green and methylene blue, are non-specific,
approved for clinical use, and suitable for perfusion imaging. Another type already in clinical use
for photodynamic therapy is photosensitizers which can be detected using MSOT and allowing
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analysis of their pharmacokinetics and biodistribution in vivo.134 Light-absorbing nanoparticles are
another exogenous contrast agent, and because of their lower photosensitivity and ability to
produce stronger photo-echoes, they offer potential advantages over organic dyes. Gold
nanoparticles, silver nanoparticles, carbon nanotubes, and iron-oxide particles have been used for
optoacoustic imaging in animals. Gold nanoparticles have the ability to produce strong
optoacoustic signals due to plasmon resonance and their absorption spectrum can be adjusted by
modifying their shape. Nanoparticle or dye can be combined with a targeting ligand to form MSOT
targeted contrast agents and used for a specific tissue which expressed specific cellular
molecules.135 For instance, MSOT imaging of integrins within tumor animals, and image matrix
metalloproteinase (MMP) activity within thyroid tumors in mice.136,137 Another powerful tool
which is already widely used in biomedical research and can also be visualized by MSOT is
fluorescent proteins. Green fluorescent protein and red fluorescent protein are examples of that.138
Table 6: Examples of optoacoustic imaging probes and their characterizations139
Probe

Type

Size (nm)

Absorption peak (nm)

Imaging target(s)

Green fluorescent
protein (GFP)

Genetically
engineered
chromophore (GEC)
GEC

NA

488

Drosophila Pupa

NA

605-665

Tumor

GEC

NA

680-800

Lymph nodes and tumor

NIR- Fluorescent
dye FD
NIR-FD
NIR-FD
Polymeric
nanostructures (NS)
Polymeric-NS
Polymeric-NS

<2

790

<2
<2
≈50

774
670
800

Brain, lymph nodes,
tumor
Tumor
Lymph nodes and tumor
Brain and deep tissue

≈100
50-200

Inorganic NP
Inorganic NP
Inorganic NP
Inorganic NP

100–1000
50-100
≈20
10–200

400, 680
Depends on
composition
600-1100
500-600
900-1000
500-800

LacZ (produced by
transgene)
Melanin (produced
by tyrosinase
transgene)
Indocyanine Green
(ICG)
IRDye800cw
Methylene blue
Polypyrrole
Porphysome
Conjugated
polymers
Gold nanorods
Gold nanoclusters
Copper sulfide
Iron oxide
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Lymph nodes
Vasculature and tumor
Tumor and lymph nodes
Tumor
Tumor
Tumor

Single-walled
carbon nanotubes
Graphene oxide
Quantum dots

Inorganic NP

5-8

600-1100

Tumor and lymph nodes

Inorganic NP
Inorganic NP

≈10
5-50

500-900
630

Tumor
Cells and lymph nodes

The CuS NP platform described in this work has been conceptually developed as a multimodality theranostic nano-platform which can accommodate a radioisotope and a magnetic
element, in addition to the CuS core with photoacoustic capability. This “all in one” platform can
be used as a single modality probe or as a combination of two or more modalities. By inserting a
radioisotope into the core/shell of NP, quantitative in vivo imaging and biodistribution analysis
can be accomplished by either PET or SPECT. Such a tool would provide robust pharmacokinetic
data and would also validate the performance of the NP imaging signal from the other modalities,
namely photoacoustic (PA) and MR imaging.
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Chapter 4: Materials and Methods
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4.1 Chemicals and suppliers
All chemical reagents involved in this work, including cell culture were used without
further modification unless it is stated in the text. Copper Chloride (CuCl2), Manganese Chloride
(MnCl2.4H2O), Sodium Sulfide (Na2S.9H2O), Poly (acrylic acid) (PAA, Mw =1800), Thiol
Polyethylene glycol Amine (HS-PEG2K-NH2), Methoxypolyethylene glycol (MPEG), Bovine
serum albumin (BSA), Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SulfoSMCC),

N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide

hydrochloride

(EDC),

N-

hydroxysuccinimide (NHS), and Cyclo (Arg-Ala-Asp-D-Phe-Lys) peptide (cRGD). All stoke
solutions, nanoparticle synthesis and purification were prepared by using nano pure water (18MΩ).
4.2 Cell lines and cell culture
The cell lines were used in this project were human lung carcinoma (A549), human colon
cancer cell (HCT116), human brain glioblastoma astrocytoma (U87-MG), human colon carcinoma
(COLO-205) and breast cancer cell lines (MDA-MB-435) and were obtained from American Type
Culture Collection (ATCC). Cell lines were maintained in humidified incubator at 37 °C and 5%
CO2. Briefly, cells were grown in Dulbecco's Modified Eagle's Medium (DMEM)/High glucose
medium supplemented with 10% fetal bovine serum (FBS), 5mM L-Glutamine, Penicillin
(100U/ml), Streptomycin (100µg/ml) and Amphotericin B (0.25 µg/ml). The cells were grown to
80 – 90 % confluency before they were used. Trypsin was used to detach the cells, and then cells
were resuspended in the media. Cells were counted by using a Neubauer chamber and the exact
number used for in vitro experiments and implantation in animals.
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4.3 Animal tumor models
All animal experiments were performed according to the policies and guidelines of the
Animal Care and Use Committee (IACUC) at Virginia Commonwealth University. Female
athymic nude mice and CD-1 mice were aged 4-6 weeks were obtained from Charles River
Laboratories. For the tumor mice model, 5X106 cells were inoculated subcutaneously into the
shoulder-side (Right and Left) of the mouse. Mice were monitored and tumor growth was
measured by using digital caliper every three days. Tumors developed within 8-10 weeks.
4.4 Synthesis of Intrinsically Radio-labeled CuS-Mn NPs
Overview: To develop the synthesis procedure for multimodality NPs. First, a nonradiolabeled Mn doped CuS NPs were synthesized and coated with different coating small
molecules or polymers to develop the chemistry of synthesis. Second, 89Zr was incorporated with
CuS-Mn NPs to develop the chemical process of intrinsically radiolabeled NPs. Another
radionuclide was used for radiolabeling which is 67Cu. 67Cu was used for incorporation with CuSMn NPs to develop [67Cu]-CuS-Mn NP. The following sections describe the development of small
NPs, composed of CuS core, which was doped with radionuclides (89Zr/67Cu) and paramagnetic
(e.g., Mn) elements, to enable MR, PET, SPECT and PA imaging in one platform (Figure 10).

Figure 10: Concept and synthetic strategy of multi-label CuS-Mn NPs
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Different approaches have been used to synthesize CuS NPs. Hydrothermal/solvent
methods, sono-chemical synthesis, microwave irradiation methods and co-precipitation method
are generally used to prepare nanostructure.77,140 The synthesis of CuS NP and Mn doped CuS-Mn
NP was done by hydrothermal reaction, without complexity and at lower temperature. A two-step
synthesis involving the reactants, copper (II) chloride (CuCl2), manganese chloride (MnCl2.4H2O),
sodium sulfide Na2S.9H2O, and different coating material were used including alginic acid, poly
(acrylic acid), citric acid, sodium citrate, and polyethylene glycol (PEG). 89Zr or 67Cu were used
for intrinsically radiolabeling the NP. 89Zr is produced by proton irradiation of a natural yttrium
target on a PET-Trace Cyclotron by IBA Molecular (Richmond, VA, USA). 89Zr activity separated
from the target using ion exchange chromatography to produce 89Zr-oxalate in a solution of 1M
oxalate.

67

Cu is produced by a photonuclear reaction from Zinc-68 (68Zn) at Argonne National

Laboratory (ANL) and received in the form of 67CuCl2. Due to its medium energy beta particle,
gamma emissions and 2.6 days half-life,

67

Cu is useful isotope can be used for therapy and

diagnosis141.
4.4.1 Synthesis of non-radiolabeled CuS NPs and CuS-Mn NPs
The synthesis of non-radiolabeled CuS NPs and CuS-Mn NPs was done as following:
1- CuCl2 (13.4mg, 0.1 mmole), MnCl2.H2O (3.4mg, 0.005-0.05 mmole) which was added
only to the CuS-Mn NP synthesis and not in CuS NP synthesis, under the existence of
organic polymers (25mg) was dissolved in 100 ml of nano-pure water.
2- In another tube, Na2S.H2O (28.8 mg, 0.12 mmole) was dissolved in 1ml of nano-pure
water.
3- A 100 µl from Na2S solution was added to 10 ml of CuCl2/MnCl2 and organic polymer
solution, dropwise and stirred for 5 min at room temperature, to form CuS-Mn core,
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followed by heating the reaction mixture to 90° C for 30 min to grow nanoparticles, which
changed color from brown to green color.
4- The obtained NPs dissolved in water and were purified by using a 3KDa molecular weight
cut-off centrifugal filter (MWCO) by centrifugation spin at 4750 rpm for 30 minutes.
5- The NPs size and surface properties can be manipulated by adjust the reaction conditions.
6- Organic polymers were used for CuS-Mn NPs synthesis, for instance: poly (acrylic acid)
(PAA), sodium citrate, alginic acid, ascorbic acid and polyethylene glycol (PEG).
7- Stability of nanoparticles, hydrodynamic size, toxicity and biodistribution depends on the
surface coating. An outline of the synthesis of coated CuS NP and CuS-Mn NPs shown in
figure 11 and 12.
Coating Ligand
PAA

CuCl / MnCl2

Na2S

2

90
º

Coating ligand

CuS
Mn

Figure 11: Schematic for the synthesis of CuS-Mn NPs

+

CuCl2+MnCl2

Na2S, 90°c for 30 min
PAA

PAA-CuS-Mn NP

+

CuCl2+MnCl2

Na2S, 90°c for 30 min
Sodium Citrate
Cit-CuS-Mn NP
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+

CuCl2+MnCl2

Na2S, 90°c for 30 min
PEG-CuS-Mn NP

Polyethylene glycol (PEG)

+
Methoxy PEG amine

CuCl2+MnCl2

Na2S, 90°c for 30 min
MPEG-CuS-Mn NP

Figure 12: Synthesis scheme and image for coated CuS-Mn NPs. Different coated material was
used to synthesis CuS-Mn NP by adding polymers or small molecules to the reaction mixture
including PAA, PEG, sodium citrate and alginic acid.
4.4.2 Synthesis of intrinsic radiolabeling 89Zr labeled CuS-Mn NPs
In order to enable PET imaging, CuS-Mn NP was incorporated with Zirconium-89 (89Zr).
89

Zr is an increasingly used radionuclide in PET imaging, particularly for radiolabeled antibodies

investigated for immunotherapy.142 This is because it has medium half-life, 3.27 days, which is
compatible with in vivo kinetics of macromolecules. The cyclotron produced 89Zr is in the form of
zirconium oxalate (89Zr-Oxalate), and in order to intrinsically introduce 89Zr in the CuS-Mn NPs
it needs to be converted to zirconium chloride 89ZrCl4 in 1M hydrochloric acid (HCl). This was
done as follows:
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89

ZrCl4 preparation
1- Sep-pak Light QMA strong anion exchange column (Waters, Inc.) was pre-washed with 6
mL acetonitrile, 10 mL 0.9% saline, and 10 mL nano-pure water.
2- The

89

Zr-Oxalate was loaded onto the cartridge and then rinsed with 40 mL nano-pure

water.
3- The 89Zr activity is retained in the column and oxalate is washed out by the water.
4- The 89Zr is eluted by 1mL 1M HCl and fractions are collected, with the highest activity
fractions combined and used for subsequent reactions.
Preparation of 89Zr labeled CuS-Mn NPs
The synthesis scheme of 89Zr labeled CuS Mn NPs is shown in figure 13, and the synthesis
procedure was done as follow:
1- CuCl2 (13.4mg, 0.1 mmole), MnCl2.H2O (3.4mg, 0.02 mmole) under existence of organic
polymers (25mg) was dissolved in 100 ml of nano-pure water.
2- For radiolabeling with

89

Zr, a 100 µl of

89

ZrCl4 (100 µCi - 940 µCi) was added to

CuCl2/MnCl2 solution before starting reaction to incorporate 89Zr in core NPs.
3- In another tube, Na2S.H2O (28.8 mg, 0.12 mmole) dissolved in 1ml of nano-pure water.
4- A 100 µl from Na2S was added to 10 ml of CuCl2/MnCl2 and organic polymer (PAA)
solution, dropwise and stirred for 5 min at room temperature, to form CuS-Mn core,
followed by heating the reaction mixture to 90° C for 30 min to grow nanoparticles, which
changed color from brow to green.
5- The obtained 89Zr labeled CuS-Mn NPs dissolved in water and were purified by using a
3KDa MWCO by centrifugation spin at 4750 rpm for 30 minutes.

48

6- This was repeated three times to remove non-NP

89

Zr associated activity, which passes

through the MWCO filter. This purification ensures that all radioactivity remaining is in
the core of the nanoparticle.
7- The NPs size and surface properties can be manipulated by adjust the reaction conditions.
Organic polymers PAA was used for coating [89Zr]-CuS-Mn NPs because it resulted of
smaller size NP.

Figure 13: Synthesis scheme for 89Zr labeled CuS-Mn NPs. 89ZrCl4 was added to the synthesis to
incorporate 89Zr into the CuS-Mn NP. PAA coated material was used to synthesis CuS-Mn NP.
4.5 Characterization of CuS-Mn NPs
The produced CuS-Mn NPs needs to be characterized to determine concentration, size and
surface charge using different methods such as an Ultraviolet-visible (UV-Vis) absorption
spectrum, dynamic light scattering (DLS), zeta potential (ZP) measurement, transmission electron
microscope (TEM) and inductively couple plasma – optical emission spectrometry (ICP-OES).
For radioactive yields, a dose calibrator to measure the activity was used during radiosynthesis and
at the end of the synthesis.
4.5.1 Absorption spectra of CuS-Mn NPs
The effect of surface coating and content of manganese on the absorption of CuS-Mn NPs
were studied and the plots showing the absorbance VS wavelength range from (400-1100)
analyzed by using an UV spectrum to see the effect of Mn concentration and surface coating. The
nanoparticles were diluted in water (1:2), and plain water was used as a blank. The absorption
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spectra of CuS NP and CuS-Mn NP were recorded by using the DU 730 spectrophotometer which
is a complete scanning UV-Vis spectrophotometer with a bandwidth of 3 nm and a wavelength
range of 190 to 1100 nm.
4.5.2 Hydrodynamic size and zeta potential measurement of CuS NPs and CuS-Mn NPs
The coating and doping Mn into CuS NPs changes its size and charge, so it is important to
determine the size and charge of the NPs. The hydrodynamic size (HD) of the nanoparticles was
measured by dynamic light scattering (DLS) using a Zeta Sizer Nano Series ZEN3600 (Malvern,
USA). The HD size of the CuS-Mn NP represents core/shell size. When the NP is coated with a
ligand, then the HD size is representative of the whole coated NP. DLS measures the diffraction
of light by particles in a solution, which fluctuate in a manner correlated to the particle size. The
diffraction can be analyzed by the system to determine the size distribution of the particles. This
method is able to determine size as small as 1-5 nm. The samples of CuS NPs, CuS-Mn with 10%
and 20% Mn concentration were diluted (1:2) with water and sonicated for 30 minutes before the
measurement.
The zeta potential is the electro-kinetic potential between the surface of nanoparticle
coating and the dispersion medium. This potential was also calculated with the Zeta Sizer Nano
Series ZEN3600, by measuring the effect of an external electric field on the nanoparticle motion.
4.5.3 Transmission electron microscope (TEM) for CuS-Mn NPs
The TEM analysis was carried out on CuS-Mn NPs. The size and morphology of
synthesized CuS-Mn NPs were investigated by EOL JEM-1400 Plus transmission electron
microscope (JEOL USA INC, Peabody, MA, USA) at an accelerating voltage of 120 kV. Images
were taken by a Gatan OneView camera (Gatan Inc., Warrendale, PA. USA). The steps of this
process are described below:
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1- First CuS-Mn NPs samples were diluted (1:5) in water and one drop was taken on copper grids
coated with carbon film. The samples of CuS-Mn NPs were left to dry for overnight.
2-The scale of the image was defined in the software by matching a scale line to the scale bar in
the TEM image.
3-The background of the image was removed by subtracting a Gaussian blur filter image with a
radius much larger than the nano-particle size (usually 150 nm).
4-The threshold of the image was adjusted to give high nanoparticle contrast and sharp edges.
5-The ‘analyze particles’ tool was used to measure the area of the particles in the image. Around
300 nanoparticles were analyzed.
4.5.4 Concentration and radioactive yield
In order to determine the concentration of CuS-Mn NPs in solution, the inductively couple
plasma – optical emission spectrometry (ICP-OES) was used to measure the concentration of Cu
and Mn. ICP-OES was also used for testing the doping of Mn in the CuS-Mn NPs. For radioactive
yield, a dose calibrator was used.
4.5.4.1 Inductively couple plasma – optical emission spectrometry (ICP-OES)
ICP-OES is an analytical system used to determine how much trace metal is in the sample.
The principle of ICP-OES depends on the fact that absorption of energy by the atoms and ions to
move electrons from the ground state to an excited state. The source of energy is argon plasma that
operate at 10,000 kelvin, which used to ionize the metal atoms in a liquid sample (nitric acid).
Those excited atoms as they are transition to a lower energy, the photons produced at specific
wavelengths that can be detected by photomultiplier tubes. The amount of light given off from the
sample is proportional to the concentration of the metal in solution. This method can detect metals
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as low as 2 parts per billion (ppb) (2 ng/mL). Agilent 5110 ICP-OES system was used for the
measurement.
Copper and manganese standards were prepared, and 7% nitric acid was used as a diluent solution
and ranged in concentration from 0.1, 0.5, 1.0, 5.0, 10, 20, 30 and 40 parts per million (ppm) and
showed linear response across that range and a standard curve was produced from the results of
the Cu and Mn standards, as seen in (Figure 14; A, B). The samples were prepared by adding a
volume (100 μL) of CuS-Mn NPs from the stock solution to 10mL 7% nitric acid solution,
expected to create a concentration within the range of the standards. The nitric acid dissolves the
CuS-Mn NPs, producing free ions of Cu and Mn in solution which can be detected.
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Figure 14: Inductively couple plasma – optical emission spectrometry (ICP-OES) calibration
curves of Copper (A) and Manganese (B) standards show good response across a wide range of
concentrations (0.1-40 PPM). Samples concentrations within this range were measured.
4.5.4.2 Radiochemical yield
A capintec CRC-15 PET chamber-based dose calibrator was used to measure

89

Zr

incorporation into CuS-Mn NPs. The measurement was taken during and at the end of
radiosynthesis of [89Zr]-CuS-Mn NPs to determine the yield and monitor the decrease of
radioactive yield.
4.6 Stability of [89Zr]-CuS-Mn NP
The purpose of radiolabeling CuS-Mn NP is to be used for in vivo biodistribution study.
So before injecting the [89Zr]-CuS-Mn NP it is important to ensure that the radioactive signal is
represent the radiolabeled NP and continue even post injection in vivo within period of time. The
MWCO filter was used for purification of the NP three times to remove unreacted 89Zr which pass
through the MWCO filter from the solution, and this indicate all the radioactivity still remining in
the nanoparticle core. To study stability of [89Zr]-CuS-Mn NP after the synthesis, Reversed phase
high-performance liquid chromatography (RP-HPLC) (Bio-scan, Model B-FC-3300) was used.
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The PAA-[89Zr]-CuS-Mn NPs samples were incubated in three different types of media, in water
solution, in ex vivo plasma for 24 hrs, and in urine sample collected 2hrs post injection of mice.
The samples were injected into RP-HPLC, and 8 x 300 mm, 200 Å Diol (YMC, Japan) sizeexclusion column was used. A 20 µL of sample solutions were injected into the HPLC with DI
water as the mobile phase and a flow rate of 1 mL/min.
4.7 MRI Performance of CuS-Mn NP
Overview: In order to enhance contrast in MRI images, paramagnetic compounds, with a
large number of unpaired electrons, such as gadolinium (Gd)-based compounds, are used as
contrast agents because they can shorten the longitudinal relaxation time (T1) and the transverse
relaxation time (T2). However, safety concerns limit the use of Gd-based contrast agents (GBCA).
The transition metal ion manganese (Mn2+), with five unpaired electrons, can produce a very
efficient positive contrast enhancement and offers an attractive alternative to GBCA. In fact,
Manganese chloride (MnCl2) has been approved by the FDA as a T1 contrast agent. The
performance of CuS-Mn NPs as a contrast agent was studied in comparison to MnCl2. The toxicity
of CuS-Mn NPs is significantly lower due to reduced Mn concentration with retention of MR
signal. Furthermore, Cu and Mn are less toxic elements than Gd and are biologically compatible.
4.7.1 MRI relaxivity study of CuS-Mn NP
The MRI performance of CuS-Mn NPs was done in comparison to MnCl2 contrast agent.
In order to determine the relationship between MR signal intensity as a functional of different
concentration of both MnCl2 and CuS-Mn NPs, a phantom study was done.
Methodology: MnCl2 and CuS-Mn NPs was prepared in Mn concentrations ranging from (0.0 mM
(Water), 0.0081mM, 0.0163mM, 0.0327mM, 0.0675mM, 0.135mM, 0.27mM and 0.54 mM). The
samples loaded in a 1ml syringe and sealed using para film on both ends (Phantom samples, Figure
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15). Each syringe labeled with the corresponding concentration. Each syringe (phantom) arranged
and taped together to make one bundle and loaded in the cradle within MRI scanner and 72mm
transmit/receive coil was used. The MR protocol with this coil results in both T1 and T2 images.
The MRI T1 and T2 signal intensity as a functional of concentration of CuS-Mn NPs and MnCl2
was calculated. MRI images of phantom for both CuS-Mn NPs and MnCl2 were taken. This
phantom was imaged by using Bruker 7T Bio spec. 70/30 small animal MRI scanner, with multiple
slice multiple echo (MSME) sequence which produce phantom image.

Figure 15: Phantom samples of MnCl2 and CuS-Mn NP. Mn concentration was in the range from
0.0mM-0.54mM.
Relaxivity calculation
1. T1 calculation: An inversion recovery pulse sequence with variable inversion time was used to
image the samples. Then, the region of interest (ROI) was drawn on each image to find the signal
intensity. The signal intensity of each concentration was plotted as a function of inversion time.
The recovery curve was then fitted into the inversion recovery equation, to yield the T1 value. The
inversion of the T1, for all the concentrations, gives the relaxation rate (R1=1/T1). The R1 values
were plotted, as a function of concentration. The slope of the straight-line fit equation gives the
relaxivity value, r1.
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2. T2 calculation: A spin-echo equation with a variable echo time was used for the same samples
above as above. The signal intensity for all the concentrations was measured as a function of echo
time, which is an exponential decay curve. This was then fitted to the exponential decay equation
to give the T2 value. The inversion of T2 is R2 (R2=1/T2). The R2 values were plotted, as a
function of concentration, and the slope of the straight-line fit gives the relaxivity value, r2.
4.7.2 In vivo MRI with CuS-Mn NP
The purpose of this experiment to evaluate the performance of CuS-Mn NPs in an in vivo
setting which is a live animal. Before imaging, the animal was anesthetized using 2% isoflurane
at room temperature until stable vital signs were established. Once the animal was sedated, it was
placed onto the imaging bed under mixtures of 2% isoflurane and O2 (1 mL/min) for the duration
of the imaging. The pre-injection MR images for mouse kidney and liver were taken and then
mouse was received intravenous (iv) injection (tail vein) with 200 µl of CuS-Mn NPs and images
for mouse kidneys and liver were taken 2 hours post injection.
4.8 Photoacoustic imaging of CuS-Mn by using (MSOT)
The CuS-Mn NP was also evaluated in terms of its photoacoustic performance in vitro and
in vivo. The CuS NP has unique properties which is the ability to absorb NIR which results an
efficient NIR and photoacoustic signal. In this study, the PA performance need to be demonstrated
using MSOT. Both phantom and animal studies were conducted to test the merit of the NP
performance as a PA agent.
4.8.1 MSOT signal as a function of CuS-Mn NP concentration
In order to determine the relationship between photoacoustic signal and NP concentration.
Such measurements determine the sensitivity of detection. To demonstrate this, a phantom study
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was carried out whereby various concentration of the CuS-Mn NPs were used and the intensity
(PA signal) of each concentration was calculated. CuS-Mn NP was prepared in the concentration
range 0 µg/ml to 100 µg/ml in water. The samples were placed in the phantom as shown in figure
16 and imaged in MSOT.

Figure 16: Agar phantom after prepared and loaded in the MSOT
Agar phantoms for MSOT imaging:
Phantoms were used to characterize injectable contrast agent in controlled setting. The
sensitivity and linearity of an optoacoustic system can be determined by using of phantoms. There
are various properties of phantoms, such as size, composition and their resulting absorption and
scattering properties. Agar phantom was made shortly before use and the preparation method was
used as follows:
1- A 20 ml syringe was used, and the front part cut off by using a scalpel, with an internal diameter
of 2 cm.
2- Intralipid (Sigma I141-100mL), 1.03 ml was heated in hot water bath.
3- To 0.75 g of Agar (Fluka, 05039-500g), a 50 ml of dH2O was added, and heated in microwave
until it boils.
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4- The agar was taken out of the microwave and immediately added to the hot intralipid and shake
gently.
5- A 15 ml of this mixture poured into a plastic adapted (distal part of cut off) syringe which having
a diameter of 2 cm. Then, immediately two 3 mm diameter straws were placed in the syringe and
was hold in position using tape. Then, cooled at room temperature for 30 minutes.
The agar phantom can be stored in the fridge in sealed container with some dH2O to keep moist.
However, the optical properties of the agar phantom change over time, so it is recommended to be
used on the same day.
MSOT image acquisition: MSOT images were acquired multispectral according to the protocol
for CuS-Mn NP (wavelengths, 700-900 nm). After image reconstruction, images corresponding to
different wavelengths were weighted with the internal laser energy values.
4.8.2 CuS-Mn NP Photoacoustic Imaging in vivo
In addition to evaluation in a phantom, the CuS-Mn NPs were also investigated in vivo.
Method: An initial baseline image was taken prior to NP administration in order to compare the
PA signal to that after injection. Mice were injected with 200 µl of CuS-Mn NPs (≈20µg/ml), and
images were taken 1 hr, 5 hrs and 24 hrs post injection.
4.8.3 Ex vivo Biodistribution of CuS-Mn NPs using ICP
CuS-Mn NPs was used for ex vivo biodistribution study and in vivo stability. Inductively coupled
plasma mass spectrometry (ICP-MS) was used to measure Cu and Mn in the tissues.
Methodology: three mice were received iv injection of a 200 µl of CuS-Mn NPs and then 24 hrs
post injection following MSOT imaging, mice were dissected, blood, major organs, and tumor
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were collected and prepared for ICP-MS measurements. The tissues need to be digested before
ICP-MS measurements, and this was done as follows:
1- The tissues were placed in a 10 mL tube, and 1mL of concentrated (70%) nitric acid was
added.
2- Tissues were allowed to be dissolved at room temperature for 24-48 hours.
3- Then, 9 ml of nano-pure water was added, and total volume became 10 ml.
4- The solution was filtered through a 0.25um filter. The final solution concentration was 7%
nitric acid.
5- Standards for Mn and Cu was made at concentrations from 0.1 PPM - 40 PPM as explained on
section 4.2.4.1.
6- ICP-MS was used to measure Mn and Cu, because it is sensitive enough for the low
concentration in tissue.
4.9 In vivo PET imaging of [89Zr]-CuS-Mn NP
Biodistribution of [89Zr]-CuS-Mn NP was determined by PET imaging. Mice PET imaging
studies were performed using a Multimodality PET/CT system (Siemens Medical Solutions Inc.,
Knoxville, TN, USA). Ten minutes prior to imaging, the animals were anesthetized using 2%
isoflurane at room temperature until stable vital signs were established. Once the animal was
sedated, it was placed onto the imaging bed under mixtures of O2 (1 mL/min) and 2% isoflurane
for the duration of the imaging. [89Zr]-CuS-Mn NPs (200µl, ≈320 µCi) was injected intravenously
in a nude mouse via the tail vein. Immediately following the injection, imaging was performed at
30 min, 2hrs, and 24hrs post injection. PET images were reconstructed using Fourier Re-binning
and Ordered Subsets Expectation Maximization (OSEM) 3D algorithm with dynamic framing
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every 60 seconds. Reconstructed images were analyzed using Inveon® Research Workplace
(IRW) software.
4.9.1 Biodistribution of PAA coated [89Zr]-CuS-Mn NPs in nude mice
Mice were injected with [89Zr]-CuS-Mn (200µl, ≈320 µCi). Mice then were dissected at
different time points post injection (30min, 2hr and 24hrs). Following animal dissections, organs,
including blood were collected. Radioactivity of each sample was measured by gamma counter.
The percentage of the injected dose per gram (%ID/g) of tissues was calculated based on the total
injected dose and organ weights. The resulting quantitative data were expressed in percent injected
dose per gram (%ID/g).
4.10 Radiolabeling of CuS-Mn NPs with 67Cu
In order to further demonstrate the intrinsic radiolabeling approach and flexibility, another
radionuclide was investigated.

67

Cu is near ideal (theranostic) radionuclide. It emits both

therapeutic radiation (beta particles) and low energy gamma photons ideal for SPECT imaging. It
has a 62 hrs half-life which is long enough to study prolonged kinetics, yet short enough so it does
not deliver high radiation dose to patients. In the course of 67Cu radiolabeling, the radionuclide
was also used to intrinsically radiolabel a NP based on cerium oxide nanoparticle (CONP) which
was previously labeled with 89Zr.13
4.10.1 Synthesis of radiolabeled [67Cu]-CuS, [67Cu]-CuS-Mn and [67Cu]-CONP NPs
A. Synthesis of [67Cu]-CuS nanoparticle:
The synthesis of ([67Cu]-CuS NPs) was done by the reaction of CuCl2 (13.4mg, 0.1 mmole), and
Na2S.H2O (0.1 mmole) in aqueous solution in the presence of organic polymers (PAA) (25mg).
The reaction involves Na2S with CuCl2 in organic polymer solution at room temperature for 5 min,
to form CuS core, followed by heating of the reaction mixture to 90° C for 30 min, to enable NPs
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growth. For radiolabeling with

67

Cu, a 100 µl of

67

solution before starting the reaction to incorporate

CuCl2 (≈150 µCi) was added to cold CuCl2
67

Cu in core NPs. The obtained NPs were

purified using a 3KDa MWCO filters by spinning the solution at 4750 rpm for 30 min at room
temperature to remove non-NP associated radioactivity.
B. Synthesis of [67Cu]-CuS-Mn nanoparticle:
The synthesis of manganese doped copper sulfide nanoparticles (CuS-Mn NPs) was done by the
reaction of CuCl2 (13.4mg, 0.1 mmole), MnCl2.H2O (3.4mg, 0.02 mmole) and Na2S.H2O (0.12
mmole) in aqueous solution in the presence of PAA (25mg). The reaction involving Na2S with
CuCl2/MnCl2 in presence of PAA solution at room temperature for 5 min, to form CuS-Mn NPs
core, followed by, heating the reaction mixture to 90° C for 30 min, to enable NP growth. For
radiolabeling with 67Cu, a 100 µl of 67CuCl2 (≈150 µCi) was added to CuCl2/MnCl2 solution before
starting reaction to incorporate 67Cu in core NPs. The obtained NPs were purified by using a 3KDa
MWCO centrifuge filters by spinning the solution at 4750 rpm for 30 min at RT to remove nonNP associated radioactivity. Synthesis scheme for 67Cu labeled CuS-Mn NPs is shown in figure
17.

Figure 17: Synthesis scheme for 67Cu labeled CuS-Mn NPs. 67CuCl2 was added to the synthesis
to incorporate 67Cu into the CuS-Mn NP. PAA coated material was used to synthesis CuS-Mn
NP. 3k MWCO filters were used for purification. HD size range was 10-35 nm.
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C. Synthesis of [67Cu]-CONPs
Another metal-based nanoparticle which is developed by our group is CONP and has been
intrinsically radiolabeled with other radionuclides such as 89Zr and 111In 39. The synthesis scheme
of [67Cu]-CONP is shown in figure 18, and the procedure as follows:
1- To a 10 ml vial, cerium nitrate Ce (NO3)3·6H2O (4mg) and polyacrylic acid (PAA) (10mg),
and a desired volume of 67CuCl2 (100 µl of ≈150 µCi) was added. Water was added to bring
the volume to 600 µl.
2- Another separate vial was filled with a diluted ammonium hydroxide NH4OH (10x dilution
of concentrated 28% NH3 stock).
3- To a 600 µl of diluted NH4OH, the prepared solution in step one was added. The solution
was stirred overnight 400 rpm at RT.
4- The obtained NPs were purified using 0.2µm filter to remove large particles and a 3 KDa
MWCO centrifuge filters by spinning the solution at 4750 rpm for 30 min at RT to remove
non-NP associated radioactivity.

Figure 18: Synthesis scheme for 67Cu labeled CONPs. 67CuCl2 was added to the synthesis to
incorporate 67Cu into the CONP. PAA coated material was used to synthesis CONP, 3k MWCO
filters were used for purification. HD size range was 3-10 nm.
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4.10.2 Radiolabeling yield measurement of [67Cu]-CuS, [67Cu]-CuS-Mn and [67Cu]-CONP
The obtained radiolabeled NPs were purified using a 3KDa MWCO centrifuge filters by
spinning the solution at 4750 rpm for 30 min at RT to remove non-NP incorporated radioactivity.
Radioactive reaction yields of 67Cu incorporated into CuS, CuS Mn and CONPs were measured
using an ionization chamber-based dose calibrator (Capintec CRC-15 PET) and gamma counting.
Measurements were taken during the radiosynthesis, end of radiosynthesis and one week after the
synthesis, to determine the radiochemical yield and retention of the radioactive at various steps.
4.10.3 Cells Uptake of [67Cu]-CuCl2 [67Cu]-CuS, [67Cu]-CuS-Mn and [67Cu]-CONP
As part of evaluation of multimodality [67Cu]-CuS-Mn NP in order to validate the nature
and chemical identity of externally detected imaging signals. The assessment of surface coating
NPs on cell binding (non-specific binding) uptake was done. To understand interactions of three
types of radiolabeled NPs with cells, three cell lines were used to determine cell uptake kinetics.
The in vitro cell uptake studies were done by using relatively low concentrations of

67

CuCl2,

[67Cu]-CuS NP, [67Cu]-CuS-Mn NP, and [67Cu]-CONP to assess the accumulation in to U87-MG,
COLO-205 and MDA-MB-435 cell lines within the time. The procedure was done as follows:
1- Three cell lines were used for cell uptake experiment, human brain glioblastoma
astrocytoma (U87-MG), human colon carcinoma (COLO-205) and breast cancer cell lines
(MDA-MB-435).
2- Cell Culture: Cell lines were maintained in humidified incubator at 37 °C and 5% CO2.
Briefly, cells were grown in DMEM/High glucose medium supplemented with 10% fetal
bovine serum (FBS), 5mM L-Glutamine, Penicillin (100U/ml), Streptomycin (100µg/ml)
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and Amphotericin B (0.25 ug/ml). The cells were grown to 70-80% confluency before they
were used.
3- Then 1X106cells were incubated with 200 µl [67Cu]-Cl2, [67Cu]-CuS NPs, [67Cu]-CuS-Mn
NPs and [67Cu]-CONP in DEME media at 37 °C and 5% CO2. Three incubation times (1hr,
4 hrs and 24 hrs) were studied in triplicate.
4- At the end of the incubation period the supernatant was collected and used for gamma
counting.
5- Cell pellet was washed with phosphate buffer saline (PBS) by spun down at 1000 rpm for
10 minutes 3 times, and wash was collected for gamma counting.
6- After third wash, cell pellet, wash 1,2,3 and supernatant were collected for gamma
counting.
4.10.4 Ex vivo Biodistribution of [67Cu]-CuS-Mn NP
The biodistribution of [67Cu]-CuS-Mn NP was done in normal female CD-1 mice.
Methodology: A nine mice (3 groups, n=3) were iv injected with a 200 μl of [67Cu]-CuS-Mn NPs
(≈ 25 μCi). Mice were dissected at 15min, 1 hr, and 24 hrs post-injection, blood samples and major
organs were collected and weighted. Gamma counter (Perkin Elmer Wallac Wizard 1470) was
used to measure radioactivity of each tissue. The percentage of the injected dose per gram (%ID/g)
of tissues was calculated from the total injected dose and organ weights. The organs removed for
counting are given below:
1-Blood, 2-Heart, 3- Liver, 4- RT.&LT. Kidney, 5-Spleen, 6-Muscle, 7-Lung, 8-Urine, 9-Feumer
bone, 10-Skull, and 11-Brain.

64

Chapter 5: Results
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5.1 Characterization of CuS-Mn NP
5.1.1 Absorption spectra of CuS-Mn NPs
The optical properties of CuS NPs and CuS-Mn NPs were characterized using UV-visible
as explained in section 4.5.1. To study the effect of surface coating and content of manganese on
the absorption of synthesized CuS NPs and CuS-Mn NPs, the absorption spectra have been
analyzed as shown in figure 19 below. All the NP preparations showed a NIR peak in the region
of 400-1100 nm. The addition of Mn and/or the surface coating still retains absorption at the NIR
region for both the addition of Mn (Fig. 19 A) and modification of surface coating (Fig. 19 B).
The magnitude of the absorption, however, has dropped slightly compared to the absorption of
neat CuS NP.

A.
B.
Figure 19: A) Absorption of PAA coated CuS NPs with different amount of Mn doping (10%,
20%, 30% and 40%). B) Absorption CuS-Mn with different surface coating (PAA, Citric acid,
Polyethylene glycol (PEG) and Cit-PEG).
5.1.2 Hydrodynamic size (HD) and zeta potential (ZP) analysis of CuS NP and CuS-Mn NP
The use of different precursor coating materials resulted in different sizes and charges of
the synthesized NP. The synthesis of Mn doped CuS NPs was successfully achieved and variation
in the amount of Mn content has also affected the HD size of the NP. The doped Mn NP reaction
yield ranged from 80% to 90% as measured by ICP. The HD size and ZP of CuS and CuS-Mn NPs
with various amount of Mn and different coating materials are summarized in table 7. Compared
to PEG and citrate, coating with PAA resulted in the smallest HD size.
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The amount of Mn doping has also impacted the HD size with 20% Mn content resulting in the
smallest size as shown in table 7 and figure 22. The zeta potential of the CuS NPs and CuS-Mn
NPs were ranged from (-22mV to -35mV), yielding a negative surface charge of the coated
nanoparticles.
Table 7: Hydrodynamic (HD) size and zeta potential of the synthesized CuS NPs, Cus-Mn NP
NPs Type

Range of size

Zeta potential (ZP)

distribution

(mV)

PAA-CuS NP

10-40 nm

-29

PAA-CuS-Mn (10%) NP

6-20 nm

-35

PAA-CuS-Mn (20%) NP

2.5-7 nm

-32

Cit-CuS-Mn NP

5-20 nm

-33

PEG-Cit-CuS-Mn NP

10-30 nm

-22

PAA-CuS NP Size Distribution by Number

PAA-CuS NP Zeta potential

Figure 20: Hydrodynamic size distribution by number (top), and zeta potential (bottom) of PAACuS NPs
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PAA-CuS-Mn (10%) NP Size Distribution by Number

PAA-CuS-Mn (10%) NP Zeta potential

Figure 21: Hydrodynamic size distribution by number (top), and zeta potential (bottom) of PAACuS-Mn (10%) NPs

PAA-CuS-Mn (20%) NP Size Distribution by Number

PAA-CuS-Mn (20%) NP Zeta potential

Figure 22: Hydrodynamic size distribution by number (top), and zeta potential (bottom) of PAACuS-Mn (20%) NPs

Cit-CuS-Mn NP Size Distribution by Number
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Cit-CuS-Mn NP Zeta potential

Figure 23: Hydrodynamic size distribution by number (top), and zeta potential (bottom) of CitCuS-Mn NPs

PEG-Cit-CuS-Mn NP Size Distribution by Number

PEG-Cit-CuS-Mn NP Zeta potential

Figure 24: Hydrodynamic size distribution by number (top), and zeta potential (bottom) of PEGCit-CuS-Mn NPs

5.1.3 Transmission electron microscope (TEM) for CuS-Mn NPs
The synthesized CuS-Mn NPs was accomplished with the synthesis method as described
in section 4.4.1. The morphology and qualitative size were characterized by TEM as described in
section 4.2.3. Representative TEM images from different field views of CuS-Mn NPs coated with
PAA are shown in (Fig. 25, A). The Samples were prepared by spreading a diluted solution of
CuS-Mn NPs onto carbon-coated copper grid. The size measured of each particle is characteristic
of the size of the CuS-Mn NPs. The size range was (≈ 5-20 nm). Figure 25, B is showing the HD
size of the same sample measured by DLS and the size range was (≈ 7-20 nm).
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A) TEM of CuS-Mn NP

B) PAA- CuS-Mn NP size distribution by number

Figure 25: A) Representative TEM images from different field views of CuS-Mn NPs coated
with PAA. Samples were prepared by spreading a dilute solution of CuS-Mn NPs onto carboncoated copper grid. The size measured of each particle is characteristic of the size of the CuS-Mn
NP. B) Size distribution by number of CuS-Mn NP measured by DLS.
5.2 MRI relaxivity study of CuS-Mn NP
The MRI signal intensity of the CuS-Mn NP was assessed as a function of Mn
concentration and compared to the intensity obtained from “bulk” MnCL2. This was tested in a
phantom study, as outlined in section 4.7.1, to obtain a relaxivity curve as shown in figures 26 and
27. Images of the phantom shown in these figures 26, 27 (A and B) indicate image enhancement
with increasing Mn concentration for both compounds. Further relaxivity characterization revealed
that CuS-Mn NP had a 2-fold increase compared to MnCl2. It can be deduced from figures 26, C
and 27, C that CuS-Mn NP shows a two-fold signal intensity higher than MnCl2 (r1: 6.1 S-1mM-1
for CuS-Mn NP vs 2.9 S-1mM-1 for MnCl2), and (r2: 151.6 S-1mM-1 for CuS-Mn NP vs 82.5 S1

mM-1 for MnCl2).
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A- CuS-Mn NP

B- MnCl2

C

Figure 26: A) CuS-Mn NPs MR T1 images of phantom. B) MnCl2 MR T1 images of phantom.
Mn concentration range, 0 mM (Water) 0.0081mM, 0.0163mM, 0.0327mM, 0.0675mM,
0.135mM, 0.27mM and 0.54 mM. C) MRI T1 signal intensity as a function of concentration of
CuS-Mn NP and MnCl2 solution in water at various concentration of Mn.
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B-MnCl2

A-CuS-Mn NP

C
C

Figure 27: A) CuS-Mn NPs MR T2 images of phantom. B) MnCl2 MR T2images of phantom.
Mn concentration range, 0 mM (Water) 0.0081mM, 0.0163mM, 0.0327mM, 0.0675mM,
0.135mM, 0.27mM and 0.54 mM. C) MRI T2 signal intensity as a functional of concentration of
CuS-Mn NP and MnCl2 solution in water at various concentration of Mn.
5.2.1 In vivo MRI with CuS-Mn NP
To validate in vitro MRI characterization of CuS-Mn NP, in vivo imaging was
accomplished as described in section 4.7.2. Figure 28 is a representative of in vivo T1 MR images
of a mouse before and 2 hours after the injection of CuS-Mn NPs. Enhancement in both the liver
(upper images) and the kidney (lower images) can be seen 2 hours after injection of CuS-Mn NP.
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Figure 28: In vivo T1 weighted MRI images of mouse pre-injection and 2 hours post-injection of
CuS-Mn NPs. Yellow arrows point to liver (top images) and kidneys (bottom images). Images
show brighter MRI signal in both liver and kidney following injection.
5.3 MSOT signal as a function of CuS-Mn NP concentration
The CuS NP has a unique property, which is the ability to absorb NIR, which results in an
efficient NIR and photoacoustic signal. After doping with Mn, the CuS-Mn NP was evaluated in
terms of its photoacoustic performance in vitro and in vivo. To test the merit of the NP performance
as a PA agent using MSOT, both phantom and animal studies were conducted.
MSOT signals as a function of CuS-Mn NP concentrations have been studied and as shown in
(Fig., 29), the PA signal increased as a function of the concentration of CuS-Mn NPs, which
indicates contrast enhancement due to the CuS-Mn NP. Such enhancement is due to the efficient
photo-absorption at the NIR region, resulting in a high PA signal.
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Figure 29: Linearity of MSOT signal as a function of CuS-Mn NP concentration. Photoacoustic
signal intensity of CuS-Mn NPs.
5.3.1 CuS-Mn NP Photoacoustic Imaging in vivo
In addition to evaluation in a phantom, the CuS-Mn NPs were also investigated in vivo.
Figure 30 illustrates lack or decreased signal prior to injection, however, increased signal is
observed following injection as soon as one hour after injection and persisted for 24 hours. Wholebody imaging showed maximum signal in the abdomen at 1 hr post injection (Fig.31), in fact
maximum signal could have been obtained less than an hour post injection as can be seen in the
figure. The rapid renal clearance of CuS-Mn NPs allows for the minimum waiting period between
injection and start of imaging. The small HD size makes the NP escape engulfing by phagocytosis
cells in blood, liver and spleen. This unique feature makes CuS-Mn NP a desirable contrast agent
with accelerated renal clearance.
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Pre-injection

1hour post-injection

5 hrs post-injection

24 hrs post-injection

Figure 30: Photoacoustic imaging of mice at pre-injection, 1, 5 and 24 hours post i.v. injection of
CuS-Mn NPs. MSOT images show PA signal in liver and kidneys as early as 1hour post injection.

Figure 31: Whole body Photoacoustic Imaging showing contrast signal of CuS-Mn NPS and
with time is decreased.
5.3.2 Multi-frame Kinetic Analysis Single Wavelength (800 nm)
Kinetic analysis was calculated for CuS-Mn NPs signal intesity. As shown in figure 32,
the presentage of optoacoustic signal in the kidneys and renal clearance were confirmed by
photoacoustic imaging. The higher signal percent was in the kidneys (Blue) as soon as the CuSMn NPs was injected, followed by the liver (Red). The liver signal was subsequently decreased,
followed by the kidneys.
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Figure 32: Presence of optoacoustic signal in the kidneys and renal clearance were confirmed by
photoacoustic imaging. MSOT kinetic analysis of CuS-Mn NP signal intensity at one wavelenght
(800) in mice kidney, spleen and liver post injection
5.3.3 Ex vivo biodistribution study of CuS-Mn NP using ICP
To further validate in vivo MSOT imaging data a biodistribution study was accumplished
as described in section 4.8.3. The bioditribution results were based on ex vivo ICP measurments
of copper and manganesse in the blood, major organs and tumors. The data was expressed as a
relative percentage uptake (organ uptake as a percentage of total Cu/Mn detected in the organ
relative to to the total elements in the rest of the organs), excluding the carcass. As seen in figure
33, the liver and the kidneys showed highest accumulation of the NP based on these measurements.
This depicts a similar pattern of accumulation as was observed from the MSOT images and kinetic
analysis.
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Biodistribution of CuSMn NP based on ICP
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Figure 33: Biodistribution of CuS-Mn NPs in single organs after 24hrs post injection. Tissues
were digested by using concentrated nitric acid, and ICP-MS was used to measure Cu and Mn.
Results from 1 group of mice (n=3) and presented as average distribution of CuS-Mn NPs per
organ, high uptake in liver and kidneys followed by the tumor and heart.
5.4. Radiolabeling of CuS-Mn NP with 89Zr
The ultimate strategy is to use Cu isotopes doped in CuS-Mn NPs because such isotopes
are chemically the same as stable copper. However, while developing the concept of doping, 89Zr
was the only radioisotope available.
The other purpose of this experiment is to demonstrate the PET capability of CuS-Mn NPs by
incorporating a PET isotope.
The synthesis of

89

Zr labeled CuS-Mn NP was conducted as explained in section 4.4.2. The

radiolabeling reaction yield of [89 Zr]-CuS-Mn NPs was > 60%.

89

Zr was used due to availability

to test the merit of intrinsic radiolabeling. 89Zr may not be the best radionuclide to incorporate into
CuS-Mn NPs, due to the element having a different chemistry and oxidation state compared to the
di-valent Cu and Mn.

77

5.4.1 Stability of PAA-[89Zr]-CuS-Mn NP
Size Exclusion Radio-HPLC was used to study the stability of PAA-Coated [89Zr]-CuSMn NP to validate the incorporation of 89Zr into the core of the NP and the radioactivity signal
represents the radiolabeled NPs. This was done in three different media: water, plasma, and urine.
Figure 34 shows the results and radioactive retention time in all samples, A), in aqueous solution
the peak had a retention time of 10.3 min; B) after incubation in mouse plasma for 24hrs, the peak
had a retention time of 10.7 min.; and C) in urine sample collected 2hrs post injection, the peak
had a retention time of 11.3 min. This demonstrates the incorporation and stability of the 89Zr into
the CuS-Mn NP.
A

B
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C

Figure 34: Radio-HPLC retention times of PAA-Coated [89Zr]-CuS-Mn NP. (A) In aqueous
solution. (B) After in vitro incubation in mouse plasma for 24 hours. (C) In urine sample
collected 2 hours post injection. Samples were injected into HPLC and detected by radioactivity
of 89Zr.
5.4.2 In vivo PET imaging of [89Zr]-CuS-Mn NP
PET imaging of [89Zr]-CuS-Mn NPs was accomplished as explained in section 4.9. 89Zr
PET imaging was performed in mice at 30 min, 2 hrs and 24 hrs post injection of (≈320 µCi)
[89Zr]-CuS-Mn NPs (0.04 µmole). There was rapid first pass renal clearance of [89Zr]-CuS-Mn
NPs as early as 30 min or indeed earlier, because of the small size of the NPs (Figure 35). The
small HD size (1-5 nm) of NPs facilitated rapid renal clearance, and the NP does not accumulate
appreciably in liver or spleen. As early as 30 min, it was already in the kidney and possibly earlier.
There is 89Zr accumulated in the bone, presumably due to detachment of the 89Zr from its NP and
subsequent accumulation in the bone, because Zirconium has a strong affinity for phosphate and
hence is a bone seeker.
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Figure 35: A female nude mice were injected iv with ≈320 µCi of [89Zr]-CuS-Mn NP, and PET
imaging was performed in mice at 30 min, 2 hrs and 24 hrs post injection. There was rapid renal
clearance of [89Zr]-CuS-Mn NPs as early as 30 min because of the small size of the NPs. The
bone uptake because of 89Zr is bone seeker.
5.4.3 Biodistribution of PAA coated [89Zr]-CuS-Mn NPs in nude mice
The in vivo image data was validated by quantitative biodistribution results showing rapid
uptake and clearance through the kidneys and less uptake in all other organs (Fig.36). The 89Zr
activity uptake seen in bone, is probably due to leakage of 89Zr ion from the NP core/shell, and
accumulating in bone lattice, as Zr is a bone seeker and has a strong affinity for phosphate. By
using another type of radionuclide such as 64Cu/67Cu, bone uptake could be avoided.
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Figure 36: Biodistribution of [89Zr]-CuS-Mn NPs at various time points 30min, 2hrs, and 24hrs.
Tissues were weighted, and gamma counted and percent injected dose per gram (%ID/g) was
calculated. High uptake in kidney and rapid renal clearance were observed, with low uptake in
liver and spleen due to small size of the NPs.
6.1. Radiolabeling of the CuS-Mn NPs with 67Cu
In order to further demonstrate the intrinsic radiolabeling approach and flexibility, another
radionuclide was investigated. The ideal radioisotopes to incorporate within the CuS NP are those
of copper, 64Cu and 67Cu. 67Cu was incorporated with three types of NPs as explained on section
5.1.2.
6.1.1 Radiolabeling yield measurements of [67Cu]-CuS, [67Cu]-CuS-Mn and [67Cu]-CONP
The Synthesis of intrinsically radiolabeled [67Cu]-CuS, [67Cu]-CuS-Mn and [67Cu]-CONP
NPs was accomplished as described in section 5.1.2. The radiochemical yields of [67Cu]-CuS NPs,
[67Cu]-CuS-Mn NPs and [67Cu]-CONP were 88±2, 98%±0 and 78%±5 respectively as shown in
(Table 8 and Fig.37). The radioactive yield stability of [67Cu]-CuS NP, [67Cu]-CuS-Mn NP and
[67Cu]-CONP was measured one week after the synthesis and was the same, excluding loss of
radioactivity due to physical decay of the radionuclide. Radiochemical yields for the incorporation
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of 67Cu into CuS-Mn NPs and CuS NPs were higher than that of CONP, presumably due to the
different chemistry of divalent Cu and Mn compared to that of Zr, indicating that incorporation of
the same elemental material results in a higher yield.
Table 8: Radiochemical yield of [67Cu]-CuS NP, [67Cu]-CuS-Mn NP and [67Cu]-CONP after the
synthesis. The measurements were taken by dose calibrator and gamma counting (n=3)
Radiochemical yield of
[67Cu]-CuS
88%±2

Radiochemical yield of
[67Cu]-CuS-Mn
98%±0

Radiochemical yield of
[67Cu]-CONP
78%±5

Radiochemical yield of [67Cu]-Cu NP,[67Cu]CuS-Mn NP,
and [67Cu]CONP
% RADIOCHEMICAL YIELD
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[67Cu]CONP

Figure 37: Radiochemical yield of [67Cu]-CuS NP, [67Cu]-CuS-Mn NP and [67Cu]-CONP. The
measurements were taken by dose calibrator and gamma counting (n=3)
6.1.2 Cell Uptake of [67Cu]-CuCl2 [67Cu]-CuS, [67Cu]-CuS-Mn and [67Cu]-CONP
Three cell lines were used for the cell uptake experiment, to determine the degree of
accumulation by cells, U87-MG, COLO-205 and MDA-MB-435. This was done as preparation of
future work to evaluate the radiolabeled CuS-Mn NPs in cancer cells and in tumor-bearing animals.
Cell uptake was done for the three types of radiolabeled nanoparticles as well as [67Cu]-Cl2, a bulk
molecule for comparison in order to test the effect of physiochemical properties on cellular uptake.
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The cell uptake results are shown in figures 38, 39, 40 and 41. [67Cu]-Cl2 shows higher uptake in
all types of the cell lines and this uptake increased over time in the range of (3% to 22%). [67Cu]CuS NPs and [67Cu]-CuS-Mn NPs showed lower uptake initially and then increased over time (≈
0.4 % to 5%). Compared to [67Cu]-CuS NPs and [67Cu]-CuS-Mn NPs, however, [67Cu]-CONPs
showed higher cellular uptake which increased over time (1% to 20%).

Uptake of [ 67 Cu]-Cl 2 in different cell lines

% UPTAKE
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24hrs

Figure 38: Uptake of [67Cu]-Cl2 in U87-MG, Colo-205 and MDA-MB435, [67Cu]-Cl2 shows higher
uptake compared with radiolabeled NPs and the cellular uptake increasing over time.

Uptake of [ 67 Cu]-CuSNPs in different cell
lines
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Figure 39: Uptake of [67Cu]-CuS NPs in U87-MG, Colo-205 and MDA-MB435. Uptake of [67Cu]CuS NPs in U87-MG was 1% at 1 hr incubation and increased over time, with Colo-205 and MDAMB-435 was ≈ 0.5% and increased at 4hrs and 24hrs.
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Uptake of [ 67 Cu]-CuSMn NPs in different cell
lines
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Figure 40: Uptake of [67Cu]-CuS-Mn NPs in U87-MG, Colo-205 and MDA-MB435. Uptake of
[67Cu]-CuS-Mn NPs in U87-MG was ≈1% at 1 hr incubation and increased over time, with Colo205 and MDA-MB-435 was ≈ 0.5% and increased at 4hrs and 24hrs.

Uptake of [ 67 Cu]-CONP in different cell lines
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Figure 41: Uptake of [67Cu]-CONP in U87-MG, Colo-205 and MDA-MB-435. Uptake of [67Cu]CONPs in U87-MG was 1% at 1 hr incubation and increased over time, with Colo-205 was ≈ 4%,
at 4hrs was 3% and 24hrs was16%, with MDA-MB-435 was ≈ 1% and increased by the time.
6.1.3 Biodistribution of [67Cu]-CuS-Mn NP
The ex vivo biodistribution for [67Cu]-CuS-Mn NPs at 15 min, 1 hr, and 24 hours post
injection is shown in (Fig., 42). The results show that the majority of [67Cu]-CuS-Mn NPs is in the
liver as a result of NPs being engulfed by liver phagocytosis predominantly due to the larger HD
size of these nanoparticles. The increase in liver accumulation over the time period studied
indicates hepatobiliary excretion.
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Biodistributiion of [ 67 Cu]CuS-Mn NPs
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Figure 42: Biodistribution of [67Cu]-CuS-Mn NPs. Uptake of the organ at various time points
15min, 1hr, and 24hrs, (n=3 per time point). Mice tail vein injected with [67Cu]-CuSMn NPs were
dissected, and tissues were weighted, and gamma counted and percent injected dose per gram
(%ID/g) was calculated. High uptake of [67Cu]-CuS-Mn NPs was by the liver followed by lung,
heart and blood.
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Chapter 6: Discussion
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6.1 Mn doped CuS NPs
Mn was successfully doped within CuS NPs with an 80-90% reaction yield. Mn doping
and PAA surface coating has the ability to reduce the size of CuS NPs. Doping 20% of Mn in CuS
NPs reduced the HD size up to ≈5 nm which is lower than the renal clearance threshold. The CuSMn NP was rapidly cleared by the kidneys because of the small size. Fast clearance is needed and
optimum NPs should do their function in the target in vivo and then be eliminated from the body.68
For example, if the NPs are used as a drug delivery vehicle , they has to deliver the drug to the
target and then degrade or clear to avoid over exposure of the body to NP and hence reduce overall
toxicity.
Absorption spectra and ZP were measured to see the effect of Mn concentrations and
different coating materials. Absorption spectra of the CuS-Mn NPs were analyzed with the
wavelength range from (400-1100 nm). The data showed a slight shift in absorption, with all
recorded peaks in the wavelength range of 900-1000 nm. This is still within the NIR range (7001100 nm) which maintains PA absorption properties of CuS-Mn NP.143 HD size and ZP of the
different types of the NPs were measured which shows the different size ranges of the CuS-Mn
NPs and the difference in range of negative charges depending on the coating materials. The
magnitude of charge of the zeta potential value affects the NP interactions with cells and tissues
in vitro and in vivo.
6.2 Intrinsically radiolabeled CuS-Mn NP
Two types of radionuclides were incorporated within the CuS-Mn NPs.

89

Zr for PET

imaging and 67Cu for SPECT. First, intrinsically radiolabeled CuS-Mn NPs were tested by using
89

Zr because of availability. The incorporation synthesis of 89Zr into CuS-Mn NP was successful,

with a radiochemical yield of >60% which enabled PET imaging and biodistribution study.
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However, 89Zr was not a good candidate due to the difference in chemistry and showed detachment
and bone accumulation in vivo.
67

Cu was used to test the intrinsic labeling within three different types of NPs CuS NP,

CuS-Mn NP and CONP.

67

Cu is a SPECT radiotracer and useful isotope that can be used for

therapy and diagnosis and has medium energy (beta particle, gamma emissions) with a half-life of
2.6 days. The incorporation of 67Cu was successfully accomplished into three different types of
the NPs which are CuS NP, CuS-Mn NP and CONP, to test the intrinsically radiolabeling and
enable SPECT imaging, cellular uptake and biodistribution study. The radiolabeling yields were
88±2, 98%±0 and 78%±5 respectively. Higher yields resulted in [67Cu]-CuS NP and [67Cu]-CuSMn NP due to this same chemistry. Intrinsically radiolabeling using the same chemical material
can result higher radiochemical efficiency and good stability.144

52

Mn and 64Cu can be tested for

intrinsically labeled CuS-Mn NP and enable PET imaging.
6.3 PET in vivo imaging of [89Zr]-CuS-Mn NPs
To enable PET imaging 89Zr was incorporated with CuS-Mn NP. In vivo PET imaging was
taken 30 min, 2hrs and 24hrs post injection. [89Zr]-CuS-Mn NPs accumulated in the kidney as
early as 30 minutes post injection and decreased over time. This is due to the small size of the NPs
which was lower than the renal threshold (HD size ≈ 5 nm) and able to be cleared by the kidneys.
This is in sharp contrast to larger NPs which lodge in the liver and spleen due to larger HD size.
The nanoparticles can be eliminated from the body by the renal or through hepatobiliary clearance.
The small size NPs can be degraded and cleared by the kidneys.13,145
89

Zr radiolabeling CuS-Mn NPs enable ex vivo biodistribution to study organ uptake and

retention within the time of the NPs. The [89 Zr]-CuS-Mn NPs showed higher uptake by the kidneys
after 30 minutes post injection, or possibly sooner, and decreased over time as shown in PET
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imaging. The liver showed lower uptake than the kidneys followed by the bones. The higher uptake
by the kidneys is because of the small HD size of the NPs which enable them to be cleared through
the kidneys as soon they are injected. The bone uptake was due to the fact that 89Zr is a bone seeker
which has a high affinity to phosphate. This result validated [89Zr]-CuS-Mn NP PET imaging.
6.4 MRI and MSOT evaluation of CuS-Mn NPs
Mn2+ is an inorganic compound and is known as a transition metal ion with five unpaired
electrons which can produce a very efficient positive contrast enhancement for MRI such as Gd.
Gd-incorporated CuS NPs has been demonstrated feasible imaging for both MR and PA.146 Mn
doped into the CuS NP to enable MR signal. Also, PA signal was assessed as a function of CuSMn NP concentration. Relaxivity study was done for CuS-Mn NP in comparison with MnCl2 and
the results show enhancement in MRI signal. The linearity relationship between r1 and r2 with the
Mn concentration was demonstrated. The CuS-Mn NP showed higher 2 folds than MnCl2. In vivo
images were taken for mouse liver and kidneys before, and two hours post injection by CuS-Mn
NPs. The enhancement in MRI signal was seen in both liver and kidneys post injection. The MRI
contrast agent has to be low toxic and with no side effect. Hence, here the small amount of Mn
doping within the CuS NP was able to enhance MRI signal, this may overcome with toxicity
problems caused by Mn based contrast agents and Gd based contrast agents.147
CuS NPs have strong NIR optical absorption properties. CuS-Mn NPs was evaluated in
terms of its ability to enhance MSOT signals. Phantom study and in vivo imaging were taken pre
and post injection (1hr, 5hrs and 24hrs) of CuS-Mn NP. In phantom, MSOT signal intensity was
increased as a function of CuS-Mn NP concentration and there was a linear relationship. In vivo
images of CuS-Mn NPs showed enhancement in MSOT signal and the signal decreased over time
because of the clearance of the NPs from the animal.
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Ni, Gd, and Fe integrated into CuS NP and successfully applied both PA and MR signal.146,148,149
CuS-Mn NP demonstrated here as a dual contrast agent for MRI and PA.
6.5 In vivo Biodistribution study of CuS-Mn NPs and [67Cu]-CuS-Mn NPs
Radiolabeling CuS-Mn NPs enable in vivo biodistribution study to evaluate organs uptake
and accumulation over time of the NPs. Gamma counting was used to count the activity. Another
biodistribution study was done for unlabeled CuS-Mn NPs and ICP-MS was used to measure Mn
and Cu in tissues.
The biodistribution study of [67Cu]-CuS-Mn NPs showed higher uptake in the liver
increased over time. The lower uptake showed in the lung, spleen, heart, blood and kidneys which
decreased over time. The [67Cu]-CuS-Mn NP was cleared from the body through hepatobiliary
excretion. This is due to the size of the [67Cu]-CuS-Mn NP which was (10-30 nm) above the size
threshold of renal clearance. In the case of the previous radiolabeling with Zr, the NP size was
(≈5nm) which cleared through the kidneys. The nanoparticles can be potentially eliminated via
renal or hepatobiliary, both demonstrated here.11,13
Another biodistribution study was done by unlabeled CuS-Mn NPs by using ICP-MS. This
was done in one time point which is 24hrs post injection in tumor model mice to assess the
accumulation of the unlabeled CuS-Mn NP in the tumor and other organs. The higher uptake was
shown in the liver followed by kidneys, tumor, heart, bone, lung and muscle. Tumor uptake was
based on the advantage of EPR effect of the NPs which adsorbed into the tumor tissue due to
vascular leakage. The uptake of CuS-Mn NPs was seen in most major organs which is important
as these organs could be targeted for cancer treatment. In future work, the plan is to conjugate the
CuS-Mn NPs with a targeting molecule to enhance tumor uptake in vivo.
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6.6 Cellular uptake of [67Cu]-CuS NP, [67Cu]-CuS-Mn NP and [67Cu]-CONP
For in vitro uptake study, the cellular uptake of all types of NPs with three different cell
lines (U87, MDA-MB435, and COLO-205) were shown to be gradually enhanced over time. The
higher uptake was seen in [67Cu]-CONP compared with [67Cu]-CuS NP and [67Cu]- CuS-Mn NP.
This is due to the smaller HD size of [67Cu]-CONP. The HD size affects the cellular uptake as
[67Cu]- CONP (3-10nm) size was smaller than [67Cu]-CuS NP (15-30nm) and [67Cu]-CuS-Mn NP
(10-30nm). These results showed that the intrinsically radiolabeled NP provides a feasible method
to quantitatively study the behavior of CuS-Mn NPs in vitro. This work was done to evaluate the
passive diffusion of the untargeted radiolabeled NPs into different cancer cell lines. The CuS-Mn
NP will be conjugated with targeting molecule (e.g peptide or mAb) to enhance tumor uptake in
vitro and in vivo.
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Chapter 7: Conjugation of CuS-Mn NPs to RGD for Integrins
targeting
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7.1 Introduction
Integrins are cell surface receptor proteins. One of the integrin family members consisting
of dimeric alpha v and beta 3 (αvβ) subunits, has been found over expressed in several types of
cancer cells, such as breast cancer and glioblastoma. Therefore, the αvβ integrin has become an
attractive molecular target for early cancer diagnosis and treatment. Cyclic arginine–glycine–
aspartic acid (cRGD) peptide has excellent selectivity and high binding affinity to αVβ3 integrin.150
The cRGD peptide has been well established and labeled with various imaging probes and
demonstrated feasibility of imaging integrin receptors in tumors.5,151
A method has been developed to conjugate CuS-Mn NPs with cRGD peptide. Characterization by
FTIR, DLS and ZP. The flow cytometry was performed on three different cell lines to assess the
integrins expression. The RGD-CuS-Mn NP then will be tested in cancer cells with different levels
of integrin expression in vivo. The NP-conjugate will be evaluated in terms of its binding to
integrin receptors expressed to varying degrees in the cancer cell lines, U87-MG, Colo-205, and
MDA-MB-345.
7.2 Synthesis of Specific Targeting CuS-Mn NP using cRGD peptide
7.2.1 Synthesis of cRGD-CuS-Mn NPs
In order to facilitate the conjugate cRGD peptide with CuS-Mn NP, the surface coating has
to be functionalized by using polyethylene glycol (PEG) or bovine serum albumin (BSA). Two
different synthesis strategies were done and the synthesis procedure for each one is described
below.
7.2.1.1Synthesis of cRGD-PEG-CuS-Mn NPs
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Synthesis of PEG-Cit-CuS-Mn NP
The synthesis of Cit-CuS-Mn NP was done as explained in the section 4.1.1. Briefly, CuCl2
(13.4mg, 0.1 mmole), MnCl2.H2O (3.4mg, 0.02 mmole) and Na2S.H2O (0.12 mmole) in aqueous
solution under existence of sodium citrate (25mg) at room temperature for 5 min, to form CuS-Mn
core, followed by heating the reaction mixture to 90° C for 30 min to grow nanoparticles. The
obtained Cit-CuS-Mn NPs was purified by using a 3K MWCO by centrifugation. To introduce
PEG into Cit-CuS-Mn NPs, the solution was suspended in 1ml H2O and 1 mg of Thiol-PEG-amine
was added to Cit-CuS-Mn NP and incubated stirring at RT overnight to form PEG-Cit-CuS-Mn
NP.
Synthesis of cRGD-PEG-CuS-Mn NP
1-The PEG-Cit-CuS-Mn NPs in PBS transferred to a 10 mL vial.
2-Sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate(Sulfo-SMCC)(5mg/ml)
was added to PEG-Cit-CuS-Mn NP under stirring and reacted for 40 min at room temperature. The
sulfo-SMCC acts as a bifunctional crosslinker between the PEG-Cit-CuS-Mn NPs and the cRGD
peptide.
3-The reaction mixture was purified by Sephadex G25 column to remove unreacted sulfo-SMCC.
4-Cyclo-RGD (1mg/ml) was mixed with activated PEG-Cit-CuS-Mn NP and stirred at room
temperature for 1 hour.
5-The cRGD-PEG-CuS-Mn NP was purified and concentrated by centrifuging through a 3,000
MW cut-off centrifuge filter at 4750 rpm for 30 min at RT. Schematic of the reaction is shown
below (Fig., 43).
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Figure 43: Schematic diagram of synthesis of cRGD-PEG-CuS-Mn NPs. CuS-Mn NPs coated with
PEG and then further conjugated with cRGD peptide. Sulfo-SMCC was used as a crosslinker
between cRGD and PEG-CuS-Mn NP.
7.2.1.2 Synthesis of cRGD-BSA-CuS-Mn NPs
As an alternative strategy previously used was done by using bovine serum albumin (BSA)
as a coating material for the CuS-Mn NPs and then N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) used as a crosslinker
between BSA and cRGD to form cRGD-BSA-CuS-Mn NPs.152 EDC is a carboxyl activate agent
which then reacted with NHS resulting unstable NHS ester which was reacted with primary amine
to form amide crosslinker bond between RGD and BSA. The strategy and schematic of the reaction
is shown below (Fig. 44).
1-0.25 g of BSA was dissolved in 7.5 mL of ultrapure water and this was used as the core reagent.
2-Next, 0.268 g of CuCl2, 0.08g MnCl2 and 0.48 g of Na2S.9H2O was dissolved in 10 mL of
ultrapure water to form the reaction solution.
3-Then, 1 mL of the copper solution was added to the BSA solution. 0.5 mL, NaOH solution was
added to adjust the pH, followed by the addition of 1.5 mL of sodium sulfide solution.
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4-Then, the mixture was heated to 90 °C and stirred for about 30 min, to form BSA-CuS-Mn NP
and ready for conjugation with RGD peptide as explained in the following.
5- The aqueous solution then cooled down to room temperature.
6-Then, 40 mg of EDC was added to the prepared BSA-CuS-Mn NP solution at room temperature
with slight stirring.
7-After 20 min, 32 mg of NHS was added to the mixture and allow to react for 2 h in the dark.
This was followed by adding 1 mL of cRGD (5 mg ml−1) to the solution.
8- The resulting mixture was vigorously stirred for 12 h.
9- The -cRGD-BSA-CuS-Mn NP solution was purified by using (0.22 µm) syringe filters and a 3k
MWCO centrifuge filters by centrifugation 3 times at 4750 rpm for 30 min at RT.
10- The purified cRGD-BSA-CuSMn NP solution was then stored at 4 °C for further use.

Figure 44: Schematic diagram of synthesis of cRGD-BSA-CuS-Mn NPs. CuS-Mn NPs coated with
BSA and then further conjugated with RGD peptide. EDC+NHS was used as a crosslinker between
cRGD and BSA-CuS-Mn NP.
7.3 Characterization
The physical characterizations of BSA-CuS-Mn NP and cRGD-BSA-CuS-Mn NP were
done by using dynamic light scattering (DLS), zeta potential to evaluate the effect of PEG, BSA
and cRGD peptide on the size and charge of the CuS-Mn NP. ICP-OES was done to measure the
amount of Cu and Mn in the NP. DLS, zeta potential and ICP-OES were done as explained in a
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previous section (4.2). Fourier Transform infrared spectroscopy (FTIR) was done to identify
surface functional groups of conjugated cRGD peptide to BSA-CuS-Mn NP and the procedure and
principle as below.
7.3.1 Fourier Transform infrared spectroscopy (FTIR)
FTIR spectroscopy is a method used to study solid, liquid, or gas by obtaining a high
resolution of wide range of infrared spectrum of absorption. The basic theory is that the bonds
between different elements absorb light at different frequencies. The frequency range is from 400
to 4000 cm-1 and at a resolution of 0.15 cm-1. In FTIR technique, the instrument produces infrared
light passes through interferometer where spectral encoding takes place. When the sample absorbs
specific frequencies of energy from the beam that enters the samples compartment, this will
characterize the sample. This spectrum provides information about the chemical bounds and
molecular structure. The BSA-CuS-Mn NP and RGD-BSA-CuS-Mn NP were dried in the oven at
45°C for 2 hrs. Dry samples as shown in (Fig., 45) were prepared to be tested for FTIR spectrum
measurement which was taken at room temperature by using Nicolet iS50 FT-IR.

Figure 45: Images of dried synthesized BSA-CuS-Mn and cRGD-BSA-CuS-Mn NPs.
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7.4 Flowcytometry analysis of αVβ3 integrins on tumor cells
Integrins receptors expressed on the surface of tumor cells with various levels and lack of
expression on other cells. It is important to study the percent of the expression of the integrins
before starting implantation in animals. This work was done in the preparation of in vitro and in
vivo work for evaluation of targeting RGD-CuS-Mn NP. The flowcytometry was used to detect
the expression level of αVβ3 integrins on the tumor cells. Three cell lines were used; human brain
glioblastoma astrocytoma (U87-MG), colon cancer cell line (Colo-205) and breast cancer cell lines
(MDA-MB-435), which were measured with a fluorescent labeled antibody.
7.4.1 Flowcytometry
First, the cells were either labeled with fluorochrome-linked antibodies or stained with
fluorescent membrane, cytoplasm, or nuclear dyes. Hence, differentiation of cell type
(immunophenotyping), the presence of membrane receptors and antigens, membrane potential,
pH, enzyme activity, and DNA content can be measured. The basic principle of flowcytometry is
that cells which passes through a laser beam can be detected and counted depending on their
properties. As the cell passes through the laser beam, light is scattered in all directions, and the
light scattered in the forward direction forward scatter (FSC), at low angles (0.5-10°) from the axis
is proportional to the square of the radius of a sphere and the size of the cell or particle. Light also
may enter the cell and be reflected by nucleus and other contents of the cell; thus, the 90° light
(right-angled, side scatter (SSC)) may be considered proportional to the granularity and internal
complexity of the cell (Figure 46). Fluorescent labeled internal or external cells components are
excited by the laser to emit light at various wavelength. Various detectors are used to measure
FSC, a line with the light beam to detect cell volume. The other detector is placed perpendicular
to the stream and used to measure SSC which detects the inner component of the cells.153
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Labeling cells by using fluorescent antibody to detect αVβ3 integrin:
Cells were labeled by using human integrin αVβ3 anti-body and the procedure was as follows:
1- 1 ×106 of the cells were collected and washed with phosphate buffer saline (PBS) three
times.
2- The cell pellets were resuspended in in 100 µl of staining buffer and were incubated with
5 μL of Fc blocker on refrigerator for 10 min, to prevent non-specific binding of the antibody.
3- Then, the cells were incubated for 20 minutes with 5 μL of human integrin αVβ3 anti-body
labeled with Alexa Fluor 488.
4- The cells were washed three times with staining buffer.
5- The cells were resuspended in 1 ml of staining buffer and analyzed by flow cytometry.
6- Unstained cells were prepared in the same procedure without florescence to be used as a
negative control.
7- The fluorescence signal of 50,000 cells were analyzed on a cell-by-cell basis using flow
cytometry.
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Figure 46: Principle of flowcytometry: Flow cytometry is a technique that colored fluorescence
cells particle move in a liquid stream through a laser light. The relative light-scattering by cells
particle is measured. Analysis and differentiation of the cells is based on their size, granularity
and which cells are carrying antibodies or dyes.
7.4.2 Fluorescence Microscope
After cells were analyzed by flow cytometry, fluorescence microscope (BZ-X800E) was
used to image the cells to assess the expression of αVβ3 integrins.
7.5 Results and discussion
7.5.1 Synthesis and Characterization of untargeted CuS-Mn NP and targeted CuS-Mn NP
The synthesis of untargeted BSA-CuS-Mn NP and targeted RGD-BSA-CuS-Mn NP was
successfully accomplished as described in section 7.2.1. BSA was used as coating material and
then RGD conjugated with BSA-CuS-Mn NP using crosslinker as described above. DLS and ZP
were done as described in section 4.2. FTIR spectra was done to confirm the conjugation of BSACuS-Mn NP with RGD peptide.
DLS and ZP of BSA-CuS-Mn NP and RGD-CuS-Mn NP
The HD size of untargeted BSA-CuS-Mn NP was ranged from 1.5-4 nm and the zetapotential was -33 mV. The HD size of targeted RGD-CuS-Mn NPs was ranged from 5-20 nm and
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zeta-potential was -28 as shown in figure 47. The increased in hydrodynamic size in RGD-BSACuS-Mn NP was due to the conjugation of RGD peptide with BSA-CuS-Mn NP.
A- HD size of BSA-CuS-Mn NP

B- ZP of BSA-CuS-Mn NP

C- HD size of RGD-BSA-CuS-Mn
NP

D-ZP of RGD-BSA-CuS-Mn NP

Figure 47: Hydrodynamic size and zeta-potential of A) HD size of BSA-CuS-Mn NPs, B) ZP of
BSA-CuS-Mn NPs, C) HD size of RGD-BSA-CS-Mn NPs and D) ZP of RGD-BSA-CuS-Mn
NPs, showing different HD size and ZP between both NPs.
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The Fourier Transform Infrared Spectroscopy (FTIR)

FTRI spectra of the peptides were measured for RGD-BSA-CuS-Mn NP and the
corresponding BSA-CuS-Mn NP (Figure 48). The characteristic IR absorption peaks at 1633 cm1

(amide I, C=O carbonyl stretch vibration) and 1388 cm-1 (amide III, C–N stretch vibration) are

representative of RGD peptides and were also found in the spectra of the corresponding NP, which
indicating the successful binding of peptide molecules to the BSA-CuS-Mn NPs. A stronger and
broad peak between 3100 cm-1 and 3400 cm-1 was observed from the FTIR spectrum of RGDBSA-CuS-Mn NP, indicating the existence of a –NH–CO– bond between BSA and RGD peptide.

Figure 48: FTIR spectra of BSA-CuS-Mn NPs and RGD-BSA-CuS-Mn NPs
7.5.2 Integrins expression levels
Three different cell lines were used to measure αVβ3 integrins expression levels by flow
cytometry as explained in section 7.4.2. The antibody-stained cells (labeled cells) were compared
with negative unstained cells (unlabeled cells). As can be seen in figure 49, A colo-205 showed a
lack in the expression of αVβ3 integrins as the cells overlays with negative unstained cells. On the
other hand, U87-MG and MDA-MB-435 showed higher expression of αVβ3 integrins where the
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cells shifted to the positive fluorescence intensity with the αVβ3 antibody-stained cells.
Fluorescence microscopic images were taken to validate the flowcytometry result (Figure 50). The
U87-MG has been known to express αVβ3 integrins and used in previous studies for imaging
targeted using RGD peptides. MDA-MB-435 also utilized in previous studies for targeting
integrins to enhance therapeutic efficacy. 5,154,155

Figure 49: Flow cytometry results of A) Colo-205, B) MDA-MB-435, C) U87-MG cells. U87MG and MDA-MB-435 cells showed increase fluorescence with the αvβ3 antibody stain
compared to unstained (negative cells), indicating that the αvβ3 integrin is expressed on the
U87MG cells and MDA-MB-435. The Colo-205 cells did not show a shift in fluorescence
intensity, indicating a lack of αVβ3 integrin expression.

Unlabeled U87.

Labeled U87

Unlabeled MDA-MB435 Labeled MDA-Mb-435

103

Unlabeled Colo-205.
Labeled Colo-205
Figure 50: Fluorescence microscope images of U87, MDA-MB-435 and Colo-205 for stained
cells with human integrin αvβ3 anti-body labeled with Alexa Fluor 488 (Labeled cells),
compared with unstained cells which not stained with human integrin αVβ3 anti-body labeled
with Alexa Fluor 488 (Unlabeled cells).
7.6 Conclusion
This work was undertaken prior to the pandemic and was intended to prepare the
groundwork for future in vivo studies. Unfortunately, the pandemic had disrupted such plans. The
development, however, has been valuable to build upon for future work.
The untargeted BSA-CuS-Mn NPs and targeted RGD-BSA-CuS-Mn NPs were
successfully synthesized and ready for in vitro and in vivo evaluation, which may enhance the
tumor uptake. Integrins expression level were studied on three cell lines (U87MG, MDA-MB435
and COLO-205). U87MG and MDA-MB435 were shown over expression of integrins than
COLO-205. The cells which showed expression of αVβ3 integrins will be candidates for future
tumor impanation in mice.
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Chapter 8: Summary and Conclusions
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8.1 Summary of Conclusion
A general strategy to synthesize a multimodality intrinsic doping/radiolabeling of CuS-Mn
NPs was demonstrated. Neither the chemical nor physical properties of radiolabeled CuS-Mn NPs
were changed by the incorporation of trace quantities of radionuclides. The NPs have been coated
with different coating polymers which facilitate water solubility, stability, biocompatibility, and
functionalization. The physiological properties and pharmacokinetics of CuS-Mn NPs can be
adjusted by modifying their surface coating. The physiochemical properties were characterized by
hydrodynamic size analysis, surface charge, radiochemical yield, absorption spectra, and relaxivity
measurements. The cell uptake and biodistribution of [67Cu]-CuS NP, [67Cu]-CuS-Mn NP and
[67Cu]-CONP, indicated obvious correlation with its size. Real time in vivo PET imaging of [89Zr]CuS-Mn NPs depicted the fate of the radiolabeled NP and revealed indications of some
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dissociation as evidenced by the bone uptake. This pharmacokinetic picture was reflected in the
data obtained by an ex vivo biodistribution study. MRI and MSOT imaging were characterized,
first in phantom and then in mice and the enhancement of MRI and PA signal were confirmed.
Doping with small amount of Mn enabled MR enhancement following intravenous (iv)
administration while maintaining PA contrast at the same time. Ex vivo biodistribution study of
[67Cu]-CuS-Mn NPs were conducted using gamma counting and another biodistribution study of
unlabeled CuS-Mn NPs were done using ICP-MS. Both showing higher uptake by the liver which
indicating hepatobiliary excretion. Finally, targeting cRGD-CuS-Mn NP was synthesized to
evaluate the active targeting in vivo. The cRGD peptide was conjugated with CuS-Mn NP through
surface functionalization approaches.
The radiolabeling method provides a useful quantitative tool to study and monitor the
behavior of the CuS-Mn NPs in vitro and in vivo. The multimodality radiolabeling CuS-Mn NPs
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can be utilized as a novel nanomedicine platform for multiple biomedical imaging and theranostic
applications. The “all in one” platform is flexible and can be used either as a single modality
imaging (PA/MRI/PET/SPECT) agent or as multi-modal agent combining two or more imaging
techniques.
8.2 Future work
The intrinsic radiolabeling of CuS-Mn NPs was established as a platform to build on in the
future. Conjugation synthesis of RGD-CuS-Mn NPs was developed and can be used for future in
vivo imaging and toxicity studies.
8.2.1 Future directions for intrinsically radiolabeled CuS-Mn NPs
Further studies could focus on three directions:
1. Investigate the in vivo targeting merit of radiolabeled NP and perform pharmacokinetic and
toxicity studies.
2. Investigate intrinsic radiolabeling of other radionuclides such as 52Mn and 64Cu to assess
not only imaging performance, but also the effect of the radionuclide on the overall
accumulation, retention and clearance, as well as toxicity related issues pertinent to the
radionuclide.
3. Explore the combination of photo-thermal and radionuclide therapy guided by imaging.
This approach could break new grounds in multi-modal therapy.
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Appendix
Research Presentation and Manuscript for publications
•

•
•
•
•

Gawi A., Gobalakrishnan S., Vijayaragavan V., Cicek H., Sun M., and Zweit J. “ImageGuided CuS-Mn Nanoparticles for Targeted Photo-thermal and Radiotherapy of Cancer”,
poster presentation at Virginia Commonwealth University, Chemistry annual poster
session (2016,2017 and 2018).
Gawi A., Gobalakrishnan S., Cicek H., Elmekharam N., McDonagh P., Wang L. and Zweit
J. “Multimodality Theranostic Copper Sulfide Nanoparticles”, oral presentation at 50th
Annual Meeting of Biomedical Engineering Society (BMES) 2018, Atlanta, Georgia.
Gawi A., Gobalakrishnan S., Cicek H., Elmekharam N., McDonagh P., Wang L., Sun M.
and Zweit J “Intrinsically Radiolabeled Copper Sulfide-Manganese Nanoparticles for
Multimodality for in vitro and in vivo study” (Manuscript in preparation).
Gawi A., Gobalakrishnan S., Cicek H., Elmekharam N., McDonagh P., Wang L., Sun M.
and Zweit J “Manganese-Doped Copper Sulfide Nanoparticles as Dual MR and
Photoacoustic Imaging Contrast Agent” (Manuscript in preparation).
Rojas J., Umretiya R., Molina-Higgins M., Gawi A., Gobalakrishnan S., and Zweit
J.“Incorporation of 67Cu within Luminescent lanthanide phosphate nanoparticles for
theranostics” (Submitted for publication).
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